EP2731949A2

EP2731949A2 - 2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors

Info

Publication number: EP2731949A2
Application number: EP12811865.0A
Authority: EP
Inventors: Ju Young Lee; Keun-Ho Ryu; Jae-Sun Kim; Yong-Hyuk Kim; Dong Chul Shin; Bong-Yong Lee; Sang-Hwan Kang; Hyun Jung Lee; Hoechul JUNG; Young Ah Shin; Euisun PARK; Jaeseung AHN
Original assignee: SK Chemicals Co Ltd
Current assignee: TIUMBIO CO., LTD.
Priority date: 2011-07-13
Filing date: 2012-07-13
Publication date: 2014-05-21
Anticipated expiration: 2032-07-13
Also published as: CN103764655B; BR112014000774A8; AU2012281281B2; BR112014000774A2; RU2612958C2; US20130018052A1; CN103764655A; US10155763B2; EP2731949B1; PL2731949T3; PT2731949T; JP6094975B2; WO2013009140A2; KR101938368B1; NO2861601T3; KR20140050048A; EP2731949A4; DK2731949T3; AU2012281281A1; CA2841252A1

Abstract

The present invention provides a novel 2-pyridyl substituted imidazole derivative, or a pharmaceutically acceptable salt or solvate thereof, which selectively inhibits the transforming growth factor-β (TGF-β) type I receptor (ALK5) and/or the activin type I receptor (ALK4); a pharmaceutical composition comprising same as an active ingredient; and a use of the 2-pyridyl substituted imidazole derivative for the manufacture of a medicament for preventing or treating a disease mediated by ALK5 and/or ALK4 receptors in a mammal.

Description

2-PYRIDYL SUBSTITUTED IMIDAZOLES

AS ALK5 AND/OR ALK4 INHIBITORS

FIELD OF THE INVENTION

The present invention relates to a novel 2-pyridyl substituted imidazole derivative or a pharmaceutically acceptable salt thereof which selectively inhibits the transforming growth factor-β (TGF-β) type I receptor (ALK5) and/or the activin type I receptor (ALK4); a pharmaceutical composition comprising same as an active ingredient; and a use of the 2-pyridyl substituted imidazole derivative for the manufacture of a medicament for preventing or treating a disease mediated by ALK5 and/or ALK4 receptors in a mammal. BACKGROUND OF THE INVENTION

TGF-β is a reacted protein that exists in at least three isoforms called TGF-βΙ, TGF^2 and TGF^3, and it controls cell proliferation and differentiation, wound healing, extracellular matrix production and immune- suppression. Other members of the transforming growth factor superfamily include activins, inhibins, bone morphogenetic proteins, growth and differentiation factors, and Miillerian inhibiting substance.

TGF-β Ι transduces signals through two highly conserved single transmembrane serine/threonine kinases, the type I (ALK5) and type II TGF-β receptors. Upon ligand- induced oligomerization, the type II receptor hyperphosphorylates serine/threonine residues in the GS region of ALK5, which leads to the activation of ALK5 by creating a binding site for Smad proteins. The activated ALK5 in turn phosphorylates Smad2 and Smad3 proteins at the C- terminal SSXS-motif, thereby causing their dissociation from the receptor and heteromeric complex formation with Smad4. Smad complexes translocate to the nucleus, assemble with specific DNA-binding co-factors and co-modulators, to finally activate the transcription of extracellular matrix components and inhibitors of matrix-degrading proteases.

Activins transduce signals in a manner similar to TGF-β. Activins bind to serine/thereonine kinase, the activin type II receptor (ActRIIB), and the activated type II receptor hyperphosphorylates serine/threonine residues in the GS region of the ALK4. The activated ALK4 in turn phosphorylates Smad2 and Smad3. The consequent formation of a hetero-Smad complex with Smad4 results in the activin-induced regulation of gene transcription.

Numerous experimental animal studies have demonstrated that the glomerular expression of TGF-β is associated with fibrosis. Such studies include Thy-1 rat model of proliferative glomerulonephritis, anti-GBM glomerulonephritis in rabbits, and 5/6 nephrectomy rat model of focal segmental glomerulosclerosis, as has been recently reviewed (see, Bitzer, M. et al., Kidney Blood Press. Res. 21 : 1-12 (1998)). Neutralizing antibodies against TGF-β improve glomerular histology in Thy-1 nephritis model (see, Border, W. A. et al., Nature 346: 371-374 (1990)).

Hyperglycemic conditions promote the TGF-β mRNA and protein syntheses in both murine proximal tubule cells and human mesangial cells (see, Wahab, N. A. et al., Biochem. J. 316:985-992 (1996); Rocco, M. V. et al., Kidney Int. 41 : 107-114 (1992)). Diabetic patients with an early kidney disease show increased accumulation of TGF-β mRNA and the expressed protein within the glomerulus (see, Yoshioka, . et al., Lab. Invest. 68: 154-163 (1993)). Kidneys with chronic renal interstitial fibrosis exhibit thickened tubular basement membranes and an expanded interstitial compartment, with interstitial fibrosis characterized by an increase in collagens I, III, V, VII, and fibronectin (see, Eddy, A. A., J. Am. Soc. Nephrol 7: 2495-2508 (1996)).

TGF-β gene expression and TGF-β protein production have been observed to increase in a variety of animal models of pulmonary fibrosis caused by bleomycin, silica, asbestos, and radiation (see, Phan, S. FI. and Kunkel, S. L, Exp.

Lung Res. 18: 29-43 (1992); Williams, A. O. et al. Am. J. Pathol. 142: 1831- 1840 (1993); Rube, C. E. et al., Int. J. Radial Oncol. Biol. Phys. 47: 1033-1042 (2000)). Coincident increase in TGF-β Ι protein and collagen gene expression in adjacent tissue slices from idiopathic pulmonary fibrosis is observed in human pulmonary fibrotic diseases {see, Broekelmann, T. J. et al., Proc. Natl. Acad. Sci. USA 88:6642-6646 (1991)). Increased TGF-β production has been observed for patients with sarcoidosis, pneumoconiosis, asbestosis, and radiation-induced fibrosis (see, Khalil, N. et al., Am. J. Respir. Cell. Mol. Biol. 14: 131-138 (1996); Jagirdar, J. et al., Environ. Health Perspect. 105:1197-1203 (1997)). Anti-TGF-β antibodies and TGF-P-soluble receptors could partially inhibit fibrosis in bleomycin-induced lung fibrosis rodent models (see, Giri, S. N. et al., Thorax 48: 959-966 (1993); Wang, Q. et al., Thorax 54: 805-812 (1999)). Tobacco smoke has been implicated as one of the most important factors that cause small airway disorders, leading to chronic obstructive pulmonary disease (COPD) (see, Wright, J. M. et al., Am. Rev. Respir. Dis. 146: 240-262 (1992)). COPD is a slowly progressive and irreversible disorder characterized by the functional abnormality of airway obstruction. TGF-β has been hypothesized to be involved in airway remodeling of the chronic airway inflammatory disorders such as COPD (see, Takizawa, H. Int. J. Mol. Med. 1: 367-378 (1998); Ning, W. et al., Proc. Natl. Acad. Sci. USA 101 : 14895-14900 (2004)).

Hepatic stellate cells (HSC) are the major source of extracellular matrix proteins in hepatic fibrosis. Extracellular matrix production by activated hepatic stellate cells markedly increases by the action of TGF-β Ι (see, Friedman, S. L., Prog. Liver Dis. 14: 101-130 (1996); Pietrangelo, A., Semin. Liver Dis. 16:13-30 (1996)). Transgenic mice that overexpress TGF-β Ι in the liver develop hepatic fibrosis as well as extrahepatic pathologies such as renal fibrosis (see, Sanderson, N. et al, Proc. Natl. Acad. Sci. USA 92:2572-2576 (1995)).

TGF-βΙ and its receptors are overexpressed in injured blood vessels and in fibroproliferative vascular lesions, leading to overproduction of extracellular matrix (see, Saltis, J. et al, Clin. Exp. Pharmacol. Physiol. 23: 193-200^1996);

McCaffrey, T. A. et al, J. Clin. Invest. 96: 2667-2675 (1995)). Anti-TGF-β antibodies reduce scar formation with the improvement of the cytoarchitecture of the neodermis in rats (see, Shah, M., J. Cell. Sci. 108: 985- 1002 (1995)), promote the healing of corneal wounds in rabbits (see, Moller- Pedersen, T., Curr. Eye Res. 17:736-747 (1998)), and accelerate wound healing of gastric ulcers in rats (see, Ernst, H., Gut 39: 172-175 (1996)).

Radiation fibrosis is a frequent sequel of therapeutic or accidental radiation overexposure of normal human tissues. TGF-βΙ plays a key role in the initiation, development, and persistence of radiation fibrosis, as has been recently reviewed (see, Martin, M. et al., Int. J. Radial Oncol. Biol. Phys. 47:277-290 (2000)).

Organ transplantation is often complicated by chronic rejection, which for some organs such as the kidney, becomes the major causes of graft loss. In human patients, chronic rejection of lung and kidney transplants is associated with increased expression of TGF-β within the tissue (see, El-Gamel, A. et al., Eur. J. Cardiothorac. Surg. 13: 424-430 (1998); Shihab, F. S. et al., J. Am. Soc. Nephrol. 6:286-294 (1995)).

TGF-β is implicated in peritoneal adhesions (see, Saed, G. M. et al., Wound Repair Regeneration 7: 504-510 (1999)). The peritoneal and sub-dermal fibrotic adhesions may be prevented by administering ALK5 and/or AL 4 inhibitors.

The tumor cells and the stromal cells within the tumors in late stages of various cancers generally overexpress TGF-β. This leads to stimulation of angiogenesis and cell motility, suppression of the immune system, and increased interaction of tumor cells with the extracellular matrix (see, Hojo, M. et al., Nature 397: 530-534 (1999)). Consequently, the tumor cells become more invasive and metastasize to other organs (see, Maehara, Y. et al., J. Clin. Oncol. 17: 607-614 (1999); Picon, A. et al., Cancer Epidemiol. Biomarkers Prev. 7:497- 504 (1998)).

Plasminogen activator inhibitor- 1 (PAI-1) is a major physiological inhibitor of both tissue-type plasminogen activator and urokinase-type plasminogen activator. Elevated levels of PAI-1 are associated with thrombosis and vascular disease, suggesting that high plasma PAI-1 may promote a hypercoagulable state by disrupting the natural balance between fibrinolysis and coagulation (see, Vaughan, D. E., J. Invest. Med. 46: 370-376 (1998)). It is known that TGF-β stimulates the expression of PAI-1 (see, Dennler, S. et al., EMBO J. 17: 3091-3100 (1998)). Accordingly, the inhibition of the production of PAI-1 with an inhibitor of the TGF-β signaling pathway would lead to novel fibrinolytic therapy.

Activin signaling and overexpression of activin are linked to pathological disorders that involve extracellular matrix accumulation and fibrosis (see, Matsuse,

T. et al., Am. J. Respir. Cell Mol. Biol. 13 : 17-24 (1995); Inoue, S. et al., Biochem.

Biophys. Res. Comm. 205:441-448 (1994); Matsuse, T. et al., Am. J. Pathol.

148:707-713 (1996); De Bleser et al., Hepatology 26:905-912 (1997); Pawlowski,

J. E., et al., J. Clin. Invest. 100:639-648 (1997); Sugiyama, M. et al., Gastroenterology 114:550-558 (1998); Munz, B. et al., EMBO J. 18:5205-5215

(1999)), inflammatory responses (see, Rosendahl, A. et al., Am. J. Respir. Cell Mol.

Biol. 25:60-68 (2001)), cachexia or wasting (see, Matzuk, M. M. et al., Proc. Natl.

Acd. Sci. USA 91 :8817-8821 (1994); Coerver, . A. et al., Mol. Endocrinol.

10:534-543 (1996); Cipriano, S. C. et al. Endocrinology 141 :2319-2327 (2000)), diseases or pathological responses in the central nervous system (see, Logan, A. et al, Eur. J. Neurosci. 11 :2367-2374 (1999); Logan, A. et al, Exp. Neurol. 159:504-

510 (1999); Masliah, E. et al, Neurochem. Int. 39:393-400 (2001); De Groot, C. J.

A. et al, J. Neuropathol. Exp. Neurol. 58: 174-187 (1999); John, G. R. et al, Nat.

Med. 8: 1115-1121 (2002)) and hypertension (see, Dahly, A. J. et al. Am. J. Physiol. Regul. Integr. Comp. Physiol. 283: R757-767 (2002)). Studies have shown that

TGF-β and activin can act together synergistically to induce extracellular matrix production (see, Sugiyama, M. et al. Gastroenterology 114:550-558 (1998)). Therefore, it becomes evident that the inhibition of ALK5 and/or ALK4 phosphorylation of Smad2 and Smad3 by the compound of the present invention would be able to treat and prevent the above mentioned disorders related to said signaling pathways.

International Publication No. WO 00/61576, and U.S. Patent Application Publication No. US 2003/0149277 Al disclose triarylimidazole derivatives and their use as ALK5 inhibitors. International Publication No. WO 01/62756 discloses pyridinylimidazole derivatives and their use as ALK5 inhibitors. International Publication No. WO 02/055077 discloses the use of imidazolyl cyclic acetal derivatives as ALK5 inhibitors. Also, International Publication No. WO 03/087304 discloses tri-substituted heteroaryls and their use as ALK5 and/or ALK4 inhibitors.

The present inventors have unexpectedly discovered that a class of 2- pyridyl substituted imidazoles function as potent and selective inhibitors of ALK5 and/or ALK4 receptors and therefore, have utility in the treatment and prevention of various diseases mediated by ALK5 and/or ALK4 receptors.

SUMMARY OF THE INVENTION

Therefore, it is an object of the present invention to provide a compound or a pharmaceutically acceptable salt thereof which selectively and effectively inhibits ALK5 and/or AL 4 receptors.

It is another object of the present invention to provide a pharmaceutical composition for preventing or treating a disease mediated by ALK5 and/or AL 4 receptors, which comprises said 2-pyridyl substituted imidazole derivative as an active ingredient.

It is a further object of the present invention to provide a use of said 2- pyridyl substituted imidazole derivative for the manufacture of a medicament for preventing or treating a disease mediated by ALK5 and/or ALK4 receptors in a mammal.

It is a further object of the present invention to provide a method for preventing or treating a disease mediated by ALK5 or ALK4 receptors, or both ALK5 and ALK4 receptors in a mammal, which comprises administering said 2- pyridyl substituted imidazole derivative to the mammal in need thereof

In accordance with one aspect of the present invention, there is provided a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof:

wherein,

K_\ is phenyl, pyridyl or thienyl fused with a structural moiety which, together with two ring members of said phenyl, pyridyl or thienyl, forms a 5-7 membered aromatic or non-aromatic ring, wherein said ring optionally contains up to three heteroatoms independently selected from O, N and S, and the fused phenyl, pyridyl or thienyl ring is optionally substituted with one or more groups independently selected from halo, -O-C_1-6 alkyl, -S-Ci_-6 alkyl, -C_1-6 alkyl, -C_1-6 haloalkyl, CN, -(ΟΗ₂)_Ρ-Ο¾₍ -O-(CH₂)_q-NR4R₅, -(CH₂)_P-NR4R₅, -NHCO-O- (CH₂)_q-NR4R₅, -NHCO-(CH₂)_p-NR4R₅, or -C₅.₁₅ heteroaryl containg up to three heteroatoms independently selected from O, N and S; or R is phenyl or pyridyl optionally substituted with one or more groups independently selected from halo, -O-C_1-6 alkyl, -S-C_1-6 alkyl, -C_1-6 alkyl, -C_1-6 haloalkyl, -CN, -(ΟΗ₂)_ρ-Ο¾_, -O- (CH₂)_q-NR₄R₅, -NH-(CH₂)_q-NR₄R₅, -(CH₂)_p-NHCOR₄, -(CH₂)_P- NHCO₂R_4; -(CH₂)_p-NHSO₂R4 or -C_5-15 heterocycle, said -C₅.₁₅ heterocycle containg up to three heteroatoms independently selected from O, N and S and being optionally substituted with C_1-6 alkyl;

R₂ is H, halo, -O-C_1-6 alkyl, -S-C_1-6 alkyl, -Ci_-6 alkyl, -C_3-7 cycloalkyl, -C₅. ₁₅ heteroaryl, -C_1-6 haloalkyl, -(CH₂)_p-OR4_; -O-(CH₂)_p-NR₄R_5; -(CH₂)_p-NR₄R₅, CN, -CONHR₄, or -SO₂NHR₄;

R₃ is H, -O-C_1-6 alkyl, -S-C_1-6 alkyl, -C,_-6 alkyl, -C_3-7 cycloalkyl, -(CH₂)_p-

N jRs, -O-(CH₂)_q-NR₄R₅, -(CH₂)_p-CONHOH, -(CH₂)_P-CN, -(CH^-CO^, - (CH₂)_p-CONR₄R₅, -(CH₂)_p-tetrazole, -(CH₂)_p-COR₄, -(CH₂)_q-(OR₆)_2j -(CH₂)_P- OR₄, -(CH₂)_P-CH=CH-CN, -(CH₂)_p-CH=CH-CO₂R4, -(CH₂)_p-CH=CH-CONR4R₅, -(CH₂)_p-NHCOR4, -(CH₂)_p-NHCO₂R4_; -(CH₂)_p-NHSO₂R4, or -(CH₂)_P-CH=CH- tetrazole;

R4 and R₅ are independently H or -C_1-6 alkyl; or R4 and R₅, together with the nitrogen atom to which they are attached, form a 3 to 6-membered aromatic or non-aromatic ring, wherein said ring optionally contains up to three heteroatoms independently selected from O, N, and S;

R6 is -Ci_-6 alkyl;

p is an integer ranging from 0 to 4;

q is an integer ranging from 2 to 5;

n is an integer ranging from 1 to 3;

X is NR₇, O, or S; and

R₇ is H, OH, -C1.6 alkyl, -C₃.₇ cycloalkyl, or -CO-C_1-6 alkyl.

In accordance with another aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating a disease mediated by ALK5 and/or AL 4 receptors, which comprises the compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as an active ingredient, and a pharmaceutically acceptable diluent or carrier.

In accordance with a further aspect of the present invention, there is provided a use of compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof for the manufacture of a medicament for preventing or treating a disease mediated by ALK5 and/or ALK4 receptors in a mammal.

In accordance with a still further aspect of the present invention, there is provided a method for preventing or treating a disease mediated by ALK5 or ALK4 receptors, or both ALK5 and ALK4 receptors in a mammal, which comprises administering the compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof to the mammal in need thereof. DETAILED DESCRIPTION OF THE INVENTION

In an embodiment of the present invention, there is provided a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof:

(I)

wherein,

Ri is phenyl, pyridyl or thienyl fused with a structural moiety which, together with two ring members of said phenyl, pyridyl or thienyl, forms a 5-7 membered aromatic or non-aromatic ring, wherein said ring optionally contains up to three heteroatoms independently selected from O, N and S, and the fused phenyl, pyridyl or thienyl ring is optionally substituted with one or more groups independently selected from halo, -O-C_1-6 alkyl, -S-C_1-6 alkyl, -Ci_-6 alkyl, -C_1-6 haloalkyl, CN, -(CH₂)_p-OR_4, -O-(CH₂)_q-NR₄R₅, -NHCO-O- (CH₂)_q-NR₄R₅, -NHCO-(CH₂)p-NR₄R₅, or -C₅.₁₅ heteroaryl containg up to three heteroatoms independently selected from O, N and S; or Ri is phenyl or pyridyl optionally substituted with one or more groups independently selected from halo, -O-C_1-6 alkyl, -S-C_1-6 alkyl, -C_1-6 alkyl, -C_1-6 haloalkyl, -CN, -(CH₂ OR_4, -O- (CH₂)_q-NR₄R₅, -NH-(CH₂)_q-NR4R₅, -(CH^-N ^, -(CH₂)_p-NHCOR₄, -(CH₂)_P- NHCO^, -( Η₂)_ρ-ΝΗ8Ο₂¾ or -C₅._I5 heterocycle, said -C₅.₁₅ heterocycle containg up to three heteroatoms independently selected from O, N and S and being optionally substituted with C_1-6 alkyl;

R₂ is H, halo, -O-C_1-6 alkyl, -S-C_1-6 alkyl, -C_1-6 alkyl, -C_3-7 cycloalkyl, -C₅. is heteroaryl, -C_1-6 haloalkyl, CN, -CONHR₄, or -SO₂NHR₄;

R₃ is H, -O-C_1-6 alkyl, -S-C_1-6 alkyl, -C_1-6 alkyl, -C_3-7 cycloalkyl, -(CH₂)_P-

NR₄R₅, -O-(CH₂)_q-NR₄R₅, -(CH₂)p-CONHOH, -(CH₂)_P-CN, -(CH₂)_p-CO₂R₄, - (CH₂)p-CONR₄R₅, -(CH₂)_p-tetrazole, -(CH₂)_p-COR₄, -(CH₂)_q-(OR₆)₂, -(CH₂)_P-

OR₄, -(CH₂)_p-CH=CH-CONR4R₅, -(CH₂)_p-NHCOR₄, -(CH₂)_p-NHCO₂R_4; -(CH₂)_p-NHSO₂R4, or -(CH₂)_P-CH=CH- tetrazole;

Re is -Ci_-6 alkyl;

p is an integer ranging from 0 to 4;

q is an integer ranging from 2 to 5;

n is an integer ranging from 1 to 3;

X is NR₇, O, or S; and

R₇ is H, OH, -Ci_-6 alkyl, -C_3-7 cycloalkyl, or -CO-C_1-6 alkyl.

In another embodiment of the present invention, Ri is phenyl, pyridyl or thienyl fused with a structural moiety which, together with two ring members of said phenyl, pyridyl or thienyl, forms a 5-6 membered aromatic or non-aromatic ring, wherein said ring optionally contains one or two heteroatoms independently ' selected from O, N and S, and the fused phenyl, pyridyl or thienyl ring is optionally substituted with one or more groups independently selected from halo, -O-C_1-6 alkyl, -S-C_1-6 alkyl, -C_1-6 alkyl, -C_1-6 haloalkyl, -CN, -(CH₂)_p-OR,_; -O- (CH₂)_q-NR4R₅, -(CH₂)p-NR4R₅, -NHCO-O-(CH₂)_q-NR₄R₅, - HCO-(CH₂)_p- NR₄R5, or -C_5-15 heteroaryl containg up to three heteroatoms independently selected from O, N and S; or R_\ is phenyl optionally substituted with one or more groups independently selected from halo, -O-Ci_-6 alkyl, -S-C^ alkyl, -Ci_-6 alkyl, - Ci_-6 haloalkyl, CN, -NH-(CH₂)_q-NR₄R₅, -(CH₂)_P-NR₄R₅, -(CH₂)_p-NHCOR,, - (CH₂)_p-NHCO₂R_4; -(CH₂)_p-NHSO₂R₄, or -C_5-15 heterocycle, said -C_5-15 heterocycle containg up to three heteroatoms independently selected from O, N and S and being optionally substituted with C_1-6 alkyl.

In a further embodiment of the present invention, is a fused ring selected from the group consisting of quinoxalinyl, quinolinyl, thienopyridinyl, benzothiazolyl, benzothiophenyl, triazoTopyridiriyl7 benzoxazolyl, quinolinyl, benzodioxolyl and benzodioxinyl, wherein said fused ring is optionally substituted with one or more groups independently selected from halo, -0-Ci_-6 alkyl, -S-C_1-6 alkyl, -C_1-6 alkyl, -C_1-6 haloalkyl, -CN, -(CH₂)_p-OR4, -O-(CH₂)_q- NR4R5, -(CH₂)_p-NR4R₅, or -C_5-15 heteroaryl, said heteroaryl containing one or two heteroatoms independently selected from O, N and S; or R\ is phenyl optionally substituted with one or two groups independently selected from halo, -O-C_1-6 alkyl, -S-C_1-6 alkyl, -C_1-6 alkyl, -C_1-6 haloalkyl, -CN, -(CH₂)_p-OR₄, -O-(CH₂)_q- NR4R₅, -NH-(CH₂)_q-NR₄R₅, -(CH₂)_P-NR₄R₅, -(CH₂)_p-NHCOR₄, -(CH₂)_P- NHCO₂R4_; -(CH₂)_p-NHSO₂R4 or -C_5-i₅ heterocycle, said heterocycle containing one or two heteroatoms independently selected from O, N and S and being optionally substituted with C 1 _-6 alkyl .

In a still further embodiment of the present invention, Κχ is benzo[l,3]dioxolyl, benzo[b]thiophenyl, 2,3-dihydro-benzo[l,4]dioxyl, benzooxazolyl, benzothiazolyl, quinoxalinyl, quinolinyl, [l,2,4]triazolo[l,5- ajpyridyl, thieno[3,2-c]pyridinyl, 2-pyrazol-l-yl-quinoxalinyl, dimethylamino- ethyl-2-yloxy-quinoxalinyl, 2-methoxy- quinoxalinyl, 3,5-dimethoxyphenyl, 4- dimethylamino-phenyl, 4-benzonitrile, 2-methyl-quinolinyl, 4-aniline, 4- acetamino-phenyl, methylsulfonylaminophenyl, tert-butyl phenylcarbamate, 4- (4-methylpiperazin-l-yl)phenyl, morpholinophenyl, m-tolyl, 4-methoxyphenyl, 4-(trifluoromethyl)phenyl, 4-(methylthio)phenyl, 3-fluoro-4-methoxyphenyl or 4- fluorophenyl.

In one embodiment of the present invention, R₂ is halo, -O-C_1-6 alkyl, -S- Ci.₆ alkyl, -C_1-6 alkyl, -C₃.₇ cycloalkyl, -C₅.₁₅ heteroaryl, -C_1-6 haloalkyl, -(CH₂)_P- OR_4, -O-(CH₂)_p-NR₄R5_! -(CH₂)_p-NR₄R5, -CN, -CONHR₄, or -SOzNHR,.

In another embodiment of the present invention, R₂ is halo, -C_1-6 alkyl, -

C_1-6 haloalkyl, or -NH₂, and is positioned ortho to the nitrogen of the pyridyl ring; preferably, R₂ is -C_1- alkyl.

In one embodiment of the present invention, R₃ is H, -O-Ci_-6 alkyl, -S-C|_-6 alkyl, -C_1-6 alkyl, C_3-7 cycloalkyl, -(CH₂)_P-NR₄R₅, -O-(CH₂)_q-NR4R₅, -(CH₂)_p- CONHOH, -(CH₂)_p-CN, -(CH₂)_p-CO₂R₄, -(CH₂)_p-CONR₄R₅, -(CH₂)_p-tetrazole, -

(CH₂)_p-OR₄, -(CH₂)_p-NHCOR4, -(CH₂)_p-NHCO₂R4, or -(CH₂)_p-NHSO₂R4. In another embodiment of the present invention, ₃ is H, -O-C_1-6 alkyl, -S- C_1-6 alkyl, -C_1-6 alkyl, -(CH^-NR^, -(CH₂)_P-CN, -(CH₂)_p-CO₂R₄, -(CH₂)_P- CONR4R5, -(CH₂)p-COR4, -(CH₂)_p-OR₄, or -(CH₂)_p-NHCOR4. In one embodiment of the present invention, R₄ and R₅ are independently

H or -C_1-4 alkyl; or R4 and R₅, together with the nitrogen atom to which they are attached, form a 3 to 6-membered aromatic or non-aromatic heterocyclic ring containing up to three heteroatoms independently selected from O, N and S, preferably, R_, and R₅ are independently H or -Ci_-6 alkyl

In one embodiment of the present invention, p is an integer ranging from

0 to 2.

In one embodiment of the present invention, q is an integer ranging from 2 to 4.

In one embodiment of the present invention, n is an integer of 1 to 3; preferably, n is an integer of 1 or 2. In one embodiment of the present invention, X is NR₇, O or S; preferably,

X is NR₇.

In one embodiment of the present invention, R₇ is H, OH, -C_1-6 alkyl, or - CO-C_1-6 alkyl; preferably, H or -CO-C_1-6alkyl.

Specific compounds of the invention which may be mentioned include the following and pharmaceutically acceptable salts thereof:

1) 1 -[6-(6-Methyl-pyridin-2-yl)-5-quinoxalin-6-yl-2,3-dihydro- imidazo[ 1 ,2-a]imidazol- 1 -yl]-ethanone;

2) 6-[2-(6-Methyl-pyridin-2-yl)-6,7-dihydro-5H-imidazo[l,2-a]imidazol-

3-yi]-quinoxaline;

3) 6-[2-(6-Methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-imidazo[l,2- a]pyrimidin-3 -y 1] -quinoxaline;

4) 6-[2-(6-Methyl-pyridin-2-yl)-6,7-dihydro-5H-imidazo[l,2-a]imidazol- 3-yl]-quinoline;

5) 6-[2-(6-Methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-imidazo[l,2- a]pyrimidin-3-yl]-quinoline;

6) 2-[2-(6-Methyl-pyridin-2-yl)-6,7-dihydro-5H-imidazo[l,2-a]imidazol- 3-yl]-thieno[3,2-c]pyridine;

7) 6-[2-(6-Methyl-pyridin-2-yl)-6,7-dihydro-5H-imidazo[ 1 ,2-a]imidazol- 3 -y 1] -benzothiazole ;

8) 5-Benzo[b]thiophen-5-yl-6-(6-methyl-pyridin-2-yl)-2,3-dihydro-lH- imidazo [ 1 ,2-a] imidazole;

9) 6-[2-(6-Methyl-pyridin-2-yl)-6,7-dihydro-5H-imidazo[l,2-a]imidazol- 3-yl]-[ 1 ,2,4]triazolo[ 1 ,5-a]pyridine;

10) 5-[2-(6-Methyl-pyridin-2-yl)-6,7-dihydro-5H-imidazo[l,2-a]imidazol- 3 -y 1] -benzoxazole ;

11) 4-[2-(6-Methyl-pyridin-2-yl)-6,7-dihydro-5H-imidazo[l,2-a]imidazol- 3-yl]-quinoline;

12) 5-Benzo[l,3]dioxol-5-yl-6-(6-methyl-pyridin-2-yl)-2,3-dihydro-lH- imidazo[ 1 ,2-a]imidazole;

13) 5-(2,3-Dihydro-benzo[l,4]dioxin-6-yl)-6-(6-methyl-pyridin-2-yl)-2,3- dihydro- 1 H-imidazo[ 1 ,2-a] imidazole;

14) 7-[2-(6-Methyl-pyridin-2-yl)-6,7-dihydro-5H-imidazo[l,2-a]imidazol- 3-yl]-2-pyrazol-l-yl-quinoxaline;

15) Dimethyl-(2-{7-[2-(6-methyl-pyridin-2-yl)-6,7-dihydro-5H- imidazo[l,2-a]imidazol-3-yl]-quinoxalin-2-yloxy}-ethyl)-amine;

16) 2-Methoxy-7-[2-(6-methyl-pyridin-2-yl)-6,7-dihydro-5H-imidazo[l,2- a]imidazol-3-yl]-quinoxaline;

17) 5-(3,5-Dimethoxyphenyl)-6-(6-methylpyridin-2-yl)-2,3-dihydro-lH- imidazo[l,2-a]imidazole;

18) N,N-Dimethyl-4-(6-(6-methylpyridin-2-yl)-2,3-dihydro-lH- imidazo [ 1 ,2-a] imidazol-5 -y l)aniline;

19) 4-(6-(6-Methylpyridin-2-yl)-2,3-dihydro-lH-imidazo[l,2-a]imidazol- 5-yl)benzonitrile;

20) 2-Methyl-6-(6-(6-methylpyridin-2-yl)-2,3-dihydro- 1 H-imidazo[ 1 ,2- a] imidazol- 5 -yl)quinoline;

21) 4-(6-(6-Methylpyridin-2-yl)-2,3-dihydro-lH-imidazo[l,2-a]imidazol- 5-yl)aniline;

22) N-(4-(6-(6-Methylpyridin-2-yl)-2,3-dihydro- lH-imidazo[ 1 ,2- a] imidazol- 5 -y l)pheny l)acetamide;

23) N-(4-(6-(6-Methylpyridin-2-yl)-2,3-dihydro-lH-imidazo[l,2- a]imidazol-5-yl)phenyl)methanesulfonamide;

24) rt-Butyl (4-(6-(6-methylpyridin-2-yl)-2,3-dihydro-lH-imidazo[l,2- a] imidazol- 5 -y l)pheny l)carbamate ;

25) 5-(4-(4-Methylpiperazin-l-yl)phenyl)-6-(6-methylpyridin-2-yl)-2,3- dihydro- 1 H-imidazo[ 1 ,2-a] imidazole;

26) 4-(4-(6-(6-Methylpyridin-2-yl)-2,3-dihydro- lH-imidazo[ 1 ,2- a]imidazol-5-yl)phenyl)morpholine;

27) 6-(6-Methylpyridin-2-yl)-5-(m-tolyl)-2,3-dihydro- lH-imidazo[ 1 ,2- ajimidazole;

28) 5-(4-Methoxyphenyl)-6-(6-methylpyridin-2-yl)-2,3-dihydro-lH- imidazo[l,2-a]imidazole;

29) 6-(6-Methylpyridin-2-yl)-5-(4-(trifluoromethyl) phenyl)-2,3-dihydro- lH-imidazo[ 1 ,2-a]imidazole;

30) 6-(6-Methylpyridin-2-yl)-5-(4-(methylthio) phenyl)-2,3-dihydro-lH- imidazo[ 1 ,2-a]imidazole;

31) 5-(3-Fluoro-4-methoxyphenyl)-6-(6-methylpyridin-2-yl)-2,3-dihydro- 1 H-imidazo[ 1 ,2-a] imidazole;

32) 5-(4-Fluorophenyl)-6-(6-methylpyridin-2-yl)-2,3-dihydro-lH- imidazo[l,2-a]imidazole;

33) l-Acetyl-6-(6-methyl-pyridin-2-yl)-5-thieno[3,2-c]pyridin-2-yl-2,3- dihydro-lH-imidazo[l,2-a]imidazole-2-carboxylic acid ethyl ester;

34) 6-(6-Methyl-pyridin-2-yl)-5-thieno[3,2-c]pyridin-2-yl-2,3-dihydro- lH-imidazo[l,2-a]imidazole-2-carboxyiic acid ethyl ester;

35) [6-(6-Methyl-pyridin-2-yl)-5-thieno[3,2-c]pyridin-2-yl-2,3-dihydro- lH-imidazo[l,2-a]imidazol-2-yl]-methanol;

36) l-Acetyl-6-(6-methyl-pyridin-2-yl)-5-thieno[3,2-c]pyridin-2-yl-2,3- dihydro- lH-imidazo[ 1 ,2-a]imidazole-2-carbonitrile;

37) 6-(6-Methyl-pyridin-2-yl)-5-thieno[3,2-c]pyridin-2-yl-2,3-dihydro- lH-imidazo[l,2-a]imidazole-2-carbonitrile;

38) 6-(6-Methyl-pyridin-2-yl)-5-thieno[3,2-c]pyridin-2-yl-2,3-dihydro- lH-imidazo[l,2-a]imidazole-2-carboxylic acid amide;

39) (6-(6-Methylpyridin-2-yl)-5-(thieno[3,2-c]pyridin-2-yl)-2,3-dihydro- lH-imidazo[l,2-a]imidazol-2-yl)methanamine;

40) N-((6-(6-Methylpyridin-2-yl)-5-(thieno[3,2-c]pyridin-2-yl)-2,3- dihydro- 1 H-imidazo[ 1 ,2-a] imidazol-2-y l)methy l)acetamide ; and

41) 6-(6-Methylpyridin-2-yl)-5-(thieno[3,2-c]pyridin-2-yl)-2,3- dihydroimidazo[2, l-b]oxazole. The inventive compound of formula (I) typically is small organic molecules (non-peptide small molecules), having a molecular weight of less than about 1,000 daltons, preferably less than about 750 daltons, more preferably less than about 500 daltons, and even more preferably less than about 300 daltons. The inventive compound of formula (I) may also be supplied in the form of a "prodrug" which is designed to release the compound of formula (I) when administered to a subject. Prodrug designs are well known in the art, and in the present invention, they depend on the nature of the substituents of the compounds of formula (I). For example, a substituent containing hydroxyl groups could be coupled to a carrier which renders the compound biologically inactive until the carrier is removed by endogenous enzymes or by enzymes targeted to a particular receptor or a specific location in the subject.

The inventive compound of formula (I) that is acidic in nature (e.g., having a carboxyl or phenolic hydroxyl group) can form a pharmaceutically acceptable salt such as a sodium, potassium, calcium, or gold salt. Also within the scope of the invention are salts formed with pharmaceutically acceptable amines such as ammonia, alkyl amines, hydroxyalkylamines, and N- methylglucamine. The inventive compound of formula (I) can be treated with an acid to form acid addition salts. Examples of such an acid include hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, methanesulfonic acid, phosphoric acid, -bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, oxalic acid, malonic acid, salicylic acid, malic acid, fumaric acid, ascorbic acid, maleic acid, acetic acid, and other mineral and organic acids well known to those skilled in the art. The acid addition salts can be prepared by treating the compound of formula (I) in its free base form with a sufficient amount of an acid (e.g., hydrochloric acid) to produce an acid addition salt (e.g., a hydrochloride salt). The acid addition salt can be converted back to its free base form by treating the salt with a suitable dilute solution of a base (e.g., sodium hydroxide, sodium bicarbonate, potassium carbonate, and ammonia). Some of the compounds of the present invention may be crystallized or recrystallized from solvents such as aqueous and organic solvents. In such cases solvates may be formed. The present invention includes within its scope stoichiometric solvates including hydrates as well as compounds containing variable amounts of water that may be produced by processes such as lyophilization.

The inventive compound of formula (I) may contain one or more asymmetric centers and thus can exist as enantiomers or diastereomers. It is to be understood that the invention includes both mixtures and separate individual isomers of the compound of formula (I). Furthermore, certain compounds of formula (I) which contain alkenyl groups may exist as cis- or tran-f-isomers. In such instance, the invention includes both mixtures and separate individual isomers. The inventive compound of formula (I) may also exist in tautomeric forms and the invention includes both mixtures and separate individual tautomers thereof. Also included in the invention are radiolabelled derivatives of the compound of formula (I) which are suitable for biological studies. As used herein, the term "alkyl" group refers to a saturated aliphatic hydrocarbon group containing 1 to 10 (e.g., 1 to 6 or 1 to 4) carbon atoms. An alkyl group can be straight or branched. Examples of an alkyl group include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert- butyl, n-pentyl, rc-heptyl, and 2-ethylhexyl. An alkyl group can be optionally substituted with one or more substituents such as alkoxy, cycloalkoxy, amino, nitro, carboxy, cyano, halo, hydroxy, sulfo, and mercapto.

As used herein, the term "cycloalkyl" group refers to an aliphatic carbocyclic ring having 3 to 10 (e.g., 4 to 8) ring carbon atoms. Examples of a cycloalkyl group include cyclopropyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantly, norbornyl, cubyl, octahydroindenyl, decahydronaphthyl, bicyclo[3.2.1]octyl, bicyclo[2.2.2]octyl, bicyclo[3.3.1]nonyl, and bicyclo[3.2.3]nonyl. As used herein, the term "haloalkyl" group refers to an alkyl group containing one or more halogen atoms. Examples of a haloalkyl group include fluoromethyl, chloromethyl, bromomethyl, and trifluoromethyl.

As used herein, the term "halogen" or "halo" group refers to fluorine, chlorine, bromine, or iodine.

As used herein, the term "heteroaryl" group refers to a monocyclic, bicyclic, or tricyclic ring structure having 5 to 15 ring atoms, at least one of which is a heteroatom (e.g., N, O, or S) and at least one ring thereof is aromatic. Examples of a heteroaryl group is pyrazolyl, pyridyl, furyl, pyrrolyl, thienyl, thiazolyl, oxazolyl, imidazolyl, indolyl. teTrazolyl, benzofuryl, bcnzothiazolyl, xanthenes, thioxanthene, phenothiazine, dihydroindole, and benzo[l,3]dioxole. As used herein, the term "heterocycle" refers to a three to seven-membered ring containing one or more heteroatomic moieties selected from S, SO, SO₂, O, N, or N-oxide, optionally substituted with one or more substituents selected from the group which includes substituted Q_-6 alkyl, substituted C_2-3 alkenyl, substituted C₂.₃ alkynyl, heteroaryl, heterocyclic, aryl, C_1-3 alkoxy optionally having one to three fluorine substituents, aryloxy, aralkoxy, acyl, aroyl, heteroaroyl, acyloxy, aroyloxy, heteroaroyloxy, sulfanyl, sulfinyl, sulfonyl, aminosulfonyl, sulfonylamino, carboxyamide, aminocarbonyl, carboxy, oxo, hydroxy, mercapto, amino, nitro, cyano, halogen, and ureido. Such a ring can be saturated or have one or more degrees of unsaturation. Such a ring may be optionally fused to one or more "heterocyclic" ring(s), aryl ring(s), heteroaryl ring(s) or carbocycle ring(s), each having optional substituents. As used herein, the term "ALK5 and/or ALK4 inhibitor" refers to a compound, other than inhibitory Smads (e.g., Smad6 and Smad7), which selectively inhibits the ALK5 and/or ALK4 receptors, preferentially over p38 or type II receptors. As used herein, the term "ALK5- and/or AL 4-mediated disease" refers to any disease which is mediated (or modulated) by ALK5 and/or ALK4, for example, a disease which is modulated by the inhibition of the phosphorylation of Smad2 and Smad3 in the TGF-β and/or activin signaling pathways. As used herein, the term "ulcers" is used to include, but not to be limited to, diabetic ulcers, chronic ulcers, gastric ulcers, and duodenal ulcers.

The inventive compound of formula (I) may be prepared by a number of methods from commercially available or known starting materials. If the starting materials are unavailable from a commercial source, they can be prepared by procedures known in the art.

The compound of formula (I) may preferably be prepared according to the procedure shown in Reaction Scheme 1 : a compound of formula (II) is subjected to bromination using bromine, followed by coupling the brominated product with a compound of formula (III) in the presence of a base in a suitable solvent. The base employable in the reaction is, but not limited to, sodium carbonate, potassium carbonate, or cesium carbonate, and the solvent employable in the reaction is, but not limited to, tetrahydrofuran, dimethylformamide, or acetonitrile.

wherein,

Ri, R₂, R₃, n and X have the same meanings as defined above.

In another method, the compound of formula (I) may be prepared according to the procedure shown in Reaction Scheme 2: a compound of formula (IV) is subjected to a cyclization reaction with a compound of formula (V) or a compound of formula (VI) in the presence of a base in a suitable solvent. The base employable in the reaction is, but not limited to, sodium carbonate, potassium carbonate, or cesium carbonate, and the solvent employable in the reaction is, but not limited to, tetrahydrofuran, dimethylformamide, or acetonitrile. <Reaction Scheme 2>

= a ogen wherein,

Ri, R₂, R₃, n and X have the same meanings as defined above.

The compound of formula (I) may also be prepared according to the procedure shown in Reaction Scheme 3. As shown in Reaction Scheme 3, a compound of formula (VII) may be subjected to a cyclization reaction with a compound of formula (V) or a compound of formula (VI) in the presence of a base in a suitable solvent, followed by treating the cyclized product with a suitable halogenating agent to obtain a compound of formula (VIII), which may then be coupled with a borate ester, boronic acid, or tin compound using Suzuki or Stille coupling method to obtain the compound of formula (I). The base employable in the reaction is, but not limited to, sodium carbonate, potassium carbonate, or cesium carbonate, and the solvent employable in the reaction is, but not limited to, tetrahydrofuran, dimethylformamide, or acetonitrile.

R=Me, n-Bu wherein,

Ri, R₂, R₃, n and X have the same meanings as defined above. Further, the compound of formula (I) wherein X is NH may be a conventional hydrolysis method as shown in Reaction Scheme 4.

wherein,

Ri, R₂, R₃ and n have the same meanings as defined above. The specific substituents of the synthetic intermediates and final products shown in the above Reaction Schemes can be present in their fully elaborated forms, in protected forms with suitable protecting groups when required as one skilled in the art, or in precursor forms which can later be converted into their final forms by methods familiar to one skilled in the art. The substituents can also be added at various stages throughout the synthetic sequence or after completion of the synthetic sequence. In many cases, commonly used functional group manipulation techinques can be used to transform one intermediate into another intermediate or one compound of formula (I) into another compound of formula (I). Substituents can also be added using common reactions, such as alkyation, acylation, halogenations, or oxidation. Such manipulations are well known in the art.

Further details for the preparation of the compound of formula (I) are found in Examples.

The compound of the present invention may be administered by any suitable routes, for example, by oral, buccal, sub-lingual, rectal, vaginal, nasal, topical or parenteral (including intravenous, intramuscular, subcutaneous, and intracoronary) administration.

The topical formulations of the present invention may be presented as, for instance, ointments, creams or lotions, eye ointments and eye or ear drops, impregnated dressings and aerosols, and may contain appropriate conventional additives such as preservatives, solvents to assist drug penetration and emollients in ointments and creams.

The formulations may also contain compatible conventional carriers, such as cream or ointment bases and ethanol or oleyl alcohol for lotions. Such carriers may be present as from about 1% by weight up to about 98% by weight of the formulation. More usually, they will form up to about 80% by weight of the formulation. For administration to man in the curative or prophylactic treatment of the disorders identified above, oral, buccal, or sub-lingual dosages of the inventive compound of formula (I) will generally be in the range of from 50 to 5000 mg daily for an average adult patient (70 kg). Thus for a typical adult patient, individual tablets or capsules contain from 25 to 500 mg of active compound, in a suitable pharmaceutically acceptable vehicle or carrier, for administration in single or multiple doses, once or several times per day. Dosages for parenteral administration will typically be within the range of from 25 to 250 mg per single dose as required. In practice, the physician will determine the actual dosing regimen which will be most suitable for an individual patient and it will vary with the age, weight and response of the particular patient. The above dosages are exemplary of the average case but there can be individual instances in which higher or lower dosage ranges may be merited, and such are within the scope of the present invention. For human use, the inventive compound of formula (I) can be administered alone, but will generally be administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice. For example, the compound may be administered orally, buccally or sublingualis in the form of tablets containing excipients such as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs or suspensions containing flavoring or coloring agents. Such liquid preparations may be prepared with pharmaceutically acceptable additives such as suspending agent {e.g., methylcellulose, a semi-synthetic glyceride such as Witepsol^® or mixtures of glycerides such as a mixture of apricot kernel oil and PEG-6 esters or mixtures of PEG-8 and caprylic/capric glycerides). The inventive compound may also be injected parenterally, for example intravenously, intramuscularly, subcutaneously or intracoronarily. For parenteral administration, the compound is best used in the form of a sterile aqueous solution which may contain other substances, for example, salts, or monosaccharides such as mannitol or glucose, to make the solution isotonic with blood.

Accordingly, the present invention provides a pharmaceutical composition for preventing or treating a disease mediated by ALK5 or AL 4 receptors, or both (ALK5- and/or ALK4- mediated diseases), which comprises the compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof as an active ingredient, together with a pharmaceutically acceptable diluent or carrier.

The invention also provides a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof; or a pharmaceutical composition containing either entity, for use in therapy.

The invention further provides a use of a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof; or a pharmaceutical composition containing either entity, for the manufacture of a medicament for the treatment of a disease, mediated by the ALK5 and/or ALK4 receptors in mammals.

In the present invention, ALK5- and/or ALK4- mediated disease may include, but are not limited to, renal-, liver- or pulmonary fibrosis, glomerulonephritis, diabetic nephropathy, lupus nephritis, hypertension-induced nephropathy, renal interstitial fibrosis, renal fibrosis resulting from complications of drug exposure, HIV-associated nephropathy, transplant necropathy, liver fibrosis due to all etiologies, hepatic dysfunction attributable to infections, alcohol-induced hepatitis, disorders of the biliary tree, pulmonary fibrosis, acute lung injury, adult respiratory distress syndrome, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, pulmonary fibrosis due to infectious or toxic agents, post-infarction cardiac fibrosis, congestive heart failure, dilated cardiomyopathy, myocarditis, vascular stenosis, restenosis, atherosclerosis, ocular scarring, corneal scarring, proliferative vitreoretinopathy, excessive or hypertrophic scar or keloid formation in the dermis occurring during wound healing resulting from trauma or surgical wounds, peritoneal and sub-dermal adhesion, scleroderma, fibrosclerosis, progressive systemic sclerosis, dermatomyositis, polymyositis, arthritis, osteoporosis, ulcers, impaired neurological function, male erectile dysfunction, Alzheimer's disease, Raynaud's syndrome, fibrotic cancers, tumor metastasis growth, radiation-induced fibrosis, and thrombosis.

In addition, the present invention provides a use of the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof for the manufacture of a medicament for preventing or treating a disease mediated by the ALK5 and/or ALK4 receptors.

The invention further provides a method of preventing or treating a disease mediated by the ALK5 and/or ALK4 receptors in a mammal, which comprises administering the compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof to the mammal in need thereof. The mammal is preferably human.

The invention further provides a method for inhibiting the TGF-β and/or activin signaling pathways in mammals, for example, inhibiting the phosphorylation of Smad2 or Smad3 by ALK5 and/or ALK4.

The invention further provides a method of reducing the accumulation of excess extracellular matrix in mammals by inhibiting the TGF-β and/or activin signaling pathways, for example, inhibiting the phosphorylation of Smad2 or Smad3 by ALK5 and/or ALK4.

The invention further provides a method of inhibiting metastasis of tumor cells in mammals by inhibiting the TGF-β signaling pathway.

The invention further provides a method of treating carcinomas mediated by an overexpression of TGF-β in mammals by inhibiting the TGF-β signaling pathway.

The present invention is further described and illustrated in examples provided below, which are, however, not intended to limit the scope of the present invention.

Intermediate 1 : Preparation of 2-tribut lstannanyl-thienof3,2-c1pyridine

Butyl lithium (BuLi) (1.6M in hexane, 1.4 mL) was slowly added to a stirred solution of thieno[3,2-c]pyridine (300 mg, 2.22 mmol) and tetramethylethylenediamine (335 mL, 2.22 mmol) in tetrahydrofuran (THF, 7.5 mL) at -78 °C. After 15 minutes, tributyltin chloride (599 mL, 2.22 mmol) was added to the. resulting mixture and stirred for 2 hours. The reaction mixture was poured into water, and the resulting solution was extracted twice with ethyl acetate (EtOAc). The combined organic layer was dried over Na₂SO₄, filtered, and concentrated under a reduced pressure. The residue was purified by mediumpressure- chromatography (MELC). on silica-gel-eluting_^with EtO AC/hexane ( 1 IX). to obtain the title compound (453.7 mg, 48%) as an oil. Ή NMR (300 MHz, CDC1₃) S 9.13 (d, 1H), 8.38 (d, 1H), 7.81 (d, 1H), 7.50 (m, 1H), 1.59(m, 6H), 1.37 (m, 6H), 1.20 (m, 6H), 0.92 (t, 9H).

Intermediate 2: Preparation of 6-(4A5.,5-tetramethyl-n,3,2^"|dioxaborolan-2-yl)- benzothiazole

A suspension of 6-bromo-benzothiazole (300 mg, 1.40 mmol), bis(pinacolato)diboron (427 mg, 1.68 mmol) and potassium acetate (KOAc)(412 mL, 4.20 mmol) in NN-dimethylformamide (DMF, 6 mL) was added to PdCl₂(dppf)₂ (57 mg, 0.07 mmol), and the mixture was stirred at 100 °C under N₂ for 4 hours. After cooling to room temperature, the mixture was diluted with brine and EtOAc, and stirred for 5 minutes. After separating the organic layer, the aqueous layer was extracted three times with EtOAc. The organic layers were combined, dried over Na₂SO₄, filtered, and concentrated under a reduced pressure. The residue was purified by MPLC on silica gel eluting with EtOAC/hexane (1/20) to obtain the title compound (329 mg, 90%) as a white solid.

1H NMR (300 MHz, CDC1₃) δ 9.06 (s, 1H), 8.46 (s, lH), 8.13 (d, 1H), 7.94 (d, 1H), 1.38 (s, 12H).

Intermediate 3: Preparation of 2-benzo[b thiophen-5-yl-4A5,5-tetramethyl-

[ 1 ,3 ,21dioxaborolane

The procedure described for Intermediate 2 was repeated except that 5- bromo-benzo [b | th i oph ene (300 mg, 1 .41 mmol) was used instead of 6-bromo- benzothiazole to obtain the title compound (290 mg, 79%) as a pale blue solid. 1H NMR (300 MHz, CDC1₃) δ 8.31 (s, 1H), 7.88 (d, 1H), 7.74 (d, 1H), 7.41 (d, 1H), 7.34 (d, 1H), 1.37 (s, 12H).

Intermediate 4: Preparation of 6-(4,4,5₁5-tetramethyl-|^"l,3,2]dioxaborolan-2-yl - 1.,2,41triazolor 1 ,5-a]pyridine

The procedure described for Intermediate 2 was repeated except that 6- Iiodo-[l,2,4]triazolo[l,5-a]pyridine (1.0 g, 4.08 mmol) was used instead of 6- bromo-benzothiazole and MPLC on silica gel elution was conducted with EtOAC/hexane (1/2) to obtain the title compound (645.4 mg, 65%) as a white solid.

1H NMR (300 MHz, CDC1₃) δ 8.95 (s, 1H), 8.35 (s, 1H), 7.81 (d, 1H), 7.72 (d, 1H), 1.36 (s, 12H).

Intermediate 5: Preparation of 5-(4A5,5-tetramethyl-[l,3,21dioxaborolan-2-yl)- benzoxazole

The procedure described for Intermediate 2 was repeated except that 5- bromo-benzoxazole (200 mg, 1.01 mmol) was used instead of 6-bromo- benzothiazole and MPLC on silica gel elution was conducted with EtOAC/hexane (1/2) to obtain the title compound (222.4 mg, 90%) as a yellow solid.

1H NMR (300 MHz, CDC1₃) δ 8.25 (s, 1H), 8.09 (s, 1H), 7.85 (d, 1H), 7.58 (d, 1H), 1.37 (s, 12H).

Intermediate 6: Preparation of 4-( A5,5-tetramethyl-|T,3,21dioxaborolan-2-yl)- quinoline

The procedure described for Intermediate 2 was repeated except that 4- bromo-quinoline (300 mg, 1.44 mmol) was used instead of 6-bromo- benzothiazole and MPLC on silica gel elution was conducted with EtOAC/CH₂Cl₂ (1/1) to obtain the title compound (110 mg, 30%) as a pale brown solid.

1H NMR (300 MHz, CDC1₃) δ 8.93 (d, 1H), 8.64 (dd, 1H), 8.11 (dd, 1H), 7.85 (d, 1H), 7.71 (m, 1H), 7.58 (m, 1H), 1.44 (s, 12H).

Intermediate 7: Preparation of 5-(4A5,5-tetramethyl-|T,3,21dioxaborolan-2-yl)- benzo(^"l,31dioxole

The procedure described for Intermediate 2 was repeated except that 5- bromo-benzo[l,3]dioxole (200 mg, 0.99 mmol) was used instead of 6-bromo- benzothiazole to obtain the title compound (220 mg, 90%) as a pale yellow oil.

1H NMR (300 MHz, CDC1₃) δ 7.35 (d, 1H), 7.23 (s, 1H), 6.82 (d, 1H), 5.95 (s, 2H), 1.32 (s, 12H).

Intermediate 8: Preparation of 6-(4,4,5,5^tetramethyl- l,3,2]dioxaborolan-2-yl)- 2,3-dihydro-benzo[l,4^~]dioxine The procedure described for Intermediate 2 was repeated except that 6- bromo-2,3-dihydro-benzo[l,4]dioxine (400 mg, 1.86 mmol) was used instead of 6-bromo-benzothiazole to obtain the title compound (431 mg, 88%) as a pale yellow oil.

Ή NMR (300 MHz, CDC1₃) δ 7.31 (d, 1H), 7.29 (dd, 1H), 6.85 (d, 1H),

4.22 (m, 4H), 1.31 (s, 12H).

Intermediate 9: Preparation of 2-imidazol-l-yl-7-(4A5,5-tetramethyl-

The procedure described for Intermediate 2 was repeated except that 7- bromo-2-imidazol-l-yl-quinoxaline (225 mg, 0.82 mmol) was used instead of 6- bromo-benzothiazole and MPLC on silica gel elution was conducted with 1% MeOH in CH₂C1₂ to obtain the title compound (130 mg, 94%) as a brown oil.

1H NMR (300 MHz, CDC1₃) δ 9.10 (s, 1H), 8.56 (d, 1H), 8.12 (s, 1H), 8.10 (dd, 1H), 7.89 (s, 1H), 7.81 (dd, 1H), 7.31 (s, 1H), 1.41 (s, 12H).

Intermediate 10: Preparation of 2-pyrazol-l-yl-7-(4A5,5-tetramethyl-

The procedure described for Intermediate 2 was repeated except that 7- bromo-2-pyrazol-l-yl-quinoxaline (200 mg, 0.73 mmol) was used instead of 6- bromo-benzothiazole and MPLC on silica gel elution was conducted with EtOAC/hexane (1/10) to obtain the title compound (220 mg, 94%) as a brown solid.

1H NMR (300 MHz, CDC1₃) δ 9.71 (s, 1H), 8.70 (d, 1H), 8.51 (s, 1H), 8.08 (d, 1H), 8.08 (d, 1H), 7.85 (d, 1H), 6.57 (dd, 1H), 1.41 (s, 12H).

Intermediate 11 : Preparation of l-[6-(6-methyl-pyridin-2-yl)-2,3-dihydro- imidazof 1 ,2-a] imidazol- 1 -yll-ethano

A solution of l-(6-methyl-pyridin-2-yl)-ethanone (5.31 g, 39.3 mmol) and 33% hydrobromic acid (HBr)/acetic acid (AcOH)(6.9 mL, 69.3 mmol) was added slowly to bromine (2 mL, 39.3 mmol), and the reaction mixture was stirred for 1 hour. The mixture was concentrated under a reduced pressure, diluted with toluene, and concentrated under a reduced pressure to obtain 2-bromo-l-(6- methyl-pyridin-2-yl)-ethanone hydrobromide (12.14 g, 105%). The bromide (10 g, 32.4 mmol) thus obtained was dissolved in water and CH₂C1₂ and then neutralized with NaHCO₃ solution. The mixture was extracted three times with CH₂C1₂, dried over anhydrous MgSO₄, filtered and evaporated to dryness under a reduced pressure. The residue was dissolved in DMF (90 mL), and N-acetyl- guanidine (9.7 g, 95.9 mmol) was added thereto. After stirring for 64 hours, the mixture was concentrated under a reduced pressure. The residue was diluted with water, extracted twice with MeOH and CH₂C1₂, dried over anhydrous MgSO₄, filtered and evaporated to form a solid under a reduced pressure. The mixture was diluted with CH₂C1₂, filtered and washed with EtOAc/hexane (1/1) to obtain N-[5-(6-methyl-pyridin-2-yl)- lH-imidazol-2-yl]-acetamide (2.29 g, 32%) as a white solid. The filtrate was further purified by MPLC on ΝΗ silica gel eluting with 1% MeOH/CH₂Cl₂ to obtain the above compound (548 mg, 5.7%).

1,2-Dibromoethane (2.7 mL, 31.8 mmol) was added to a mixture of the above compound (2.29 g, 10.6 mmol) and Cs₂CO₃ (17 g, 53.0 mmol) in DMF (130 mL) at 80 °C, and the reaction mixture was stirred for 5 hours. After cooling to room temperature, the mixture was filtered through celite, washed with DMF, and concentrated under a reduced pressure. The residue was diluted with water, extracted three times with CH₂C1₂, dried over anhydrous MgSO₄, filtered and evaporated under a reduced pressure. The residue was purified by MPLC on NH silica gel eluting with CH₂Cl₂/hexane/EtOAc (3/1/0.5→ 3/0/1) to obtain the title compound (1.27 g, 49%) as a white solid.

1H NMR (300 MHz, CDC1₃) δ 7.68 (d, 1H), 7.57 (t, 1H), 7.46 (s, 1H), 6.98 (d, 1H), 4.46 (m, 2H), 4.15 (m, 2H), 2.70 (s, 3H), 2.54 (s, 3H).

Intermediate 12: Preparation of l-[5-bromo-6-(6-methyl-pyridin-2-yl)-2,3- dihydro-imidazor 1 ,2-aT imidazol- 1 -y -ethanone

To a stirred solution of l-[6-(6-methyl-pyridin-2-yl)-2,3-dihydro- imidazo[l,2-a]imidazol-l-yl]-ethanone (Intermediate 11, 1.27 g, 5.22 mmol) in dry CH₂C1₂ (50 mL) at 0°C was added N-bromosuccinimide (929 mg, 5.22 mmol) portionwise and the mixture was stirred for 20 minutes. The reaction mixture was diluted with water, extracted three times with CH₂C1₂, dried over anhydrous MgSO₄, filtered and evaporated under a reduced pressure. The residue was purified by MPLC on ΝΗ silica gel eluting with CH₂Cl₂/hexane/EtOAc (3/1/0.5→ 3/1/1) to obtain the title compound (1.62 g, 96%) as a white solid.

1H NMR (300 MHz, CDC1₃) δ 7.68 (d, 1H), 7.59 (t, 1H), 7.03 (d, 1H), 4.48 (m, 2H), 4.12 (m, 2H), 2.67 (s, 3H), 2.60 (s, 3H).

Intermediate 13: Preparation of 2-(2-(benzylsulfonyl)-lH-imidazol-4-yl)-6- methylpyridine

Benzyl bromide (1.71 g, 10 mmol) was added to a mixture of thiourea (761 mg, 10 mmol) in isopropyl alcohol (30 mL), and the mixture was stirred at 85 °C for 1 hour. After cooling to room temperature, the mixture was concentrated under a reduced pressure, diluted with toluene, and concentrated under a reduced pressure to obtain benzyl carbamimidothioate hydrobromide (2.48 g, 100%) as a white solid. 2-bromo-l-(6-methyl-pyridin-2-yl)-ethanone hydrobromide {see the procedure described for Intermediate 1 1, 294 mg, 1 mmol) was added to a mixture of the above compound (741 mg, 3 mmol) and Na₂CO₃ (435 mg, 4.1 mmol) in DMF (3 mL) at 50 °C, and the mixture was stirred for 16 hours. After cooling to room temperature, the mixture was diluted with brine and CH2CI2, and stirred for 5 minutes. After separating organic layer, the aqueous layer was extracted three times with CH₂C1₂, dried over Na₂SO₄, filtered, and concentrated under a reduced pressure. The residue was purified by MPLC on NH silica gel eluting with EtOAC/CH₂Cl₂ (0%→ 20%) to obtain 2-(2- (benzylthio)-lH-imidazol-4-yl)-6-methylpyridine (177 mg, 63%) as a pale yellow oil. To a stirred solution of the oil (177 mg, 0.63 mmol) in dry CH₂C1₂ at 0 °C was added 3-chloroperbenzoic acid (310 mg, 1.38 mmol) and the mixture was stirred for 1 hour. The mixture was diluted with H₂O and CH₂C1₂ and then stirred for 5 minutes. After separating organic layer, the aqueous layer was extracted twice with CH₂C1₂. The organic layers were combined, dried over Na₂SO₄, filtered and concentrated under a reduced pressure. The residue was purified by MPLC on NH silica gel eluting with MeOH/CH₂Cl₂ (5%) to obtain the title compound (113 mg, 58%) as a white oil.

MS (ESI) m/z 314.05 (MH⁺).

1H NMR (300 MHz, CDC1₃) δ 7.64 (m, 2H), 7.26 (m, 3H), 7.16 (m, 3H), 7.06 (d, 1H), 4.61 (s, 2H), 2.50 (s, 3H).

Intermediate 14: Preparation of 5-bromo-6-(6-methylpyridin-2-yl -2,3- dih droimidazo[2J-b]oxazole

2-Bromoethanol (135 iL, 1.92 mmol) was added to a mixture of 2-(2- (benzylsulfonyl)-lH-imidazol-4-yl)-6-methylpyridine (Intermediate 13, 200 mg, 0.64 mmol) and Cs₂CO₃ (831 mg, 2.56 mmol) in DMF (4 mL) at 80 °C, and the reaction mixture was stirred for 4 hours. After cooling to room temperature, the mixture was diluted with saturated NH₄C1 solution and CH₂C1₂ and stirred for 5 minutes. After separating organic layer, the aqueous layer was extracted twice with CH₂C1₂. The organic layers were combined, dried over Na₂SO₄, filtered, and concentrated under a reduced pressure. The residue was purified by MPLC on NH silica gel eluting with EtOAC/CH₂Cl₂ (0% → 30%) to obtain 2-(2- (benzylsulfonyl)-4-(6-methylpyridin-2-yl)-lH-imidazol-l-yl)ethanol (130 · mg, 57%) as a white foam. Sodium hydride (14.5 mg, 0.36 mmol) was added to a solution of the above compound (130 mg, 0.36 mmol) in dry THF (6 mL) at room temperature and the mixture was stirred for 2 hours. The mixture was diluted with H₂O and EtOAC, and stirred for 5 minutes. After separating organic layer, the aqueous layer was extracted twice with MeOH/CH₂Cl₂ (3%). The combined organic layer was dried over Na₂SO₄, filtered, and concentrated under a reduced pressure. The residue was purified by MPLC oil NH silica gel eluting with EtOAC/CH₂Cl₂ (0% → 10%) to obtain 6-(6-methylpyridin-2-yl)-2,3- dihydroimidazo[2,l-b]oxazole (54 mg, 74%) as a white solid. The resulting compound was then reacted as described in Intermediate 12 to afford after MPLC on NH silica gel eluting with CH₂Cl₂/hexane (50%→ 100%), the title compound (35 mg, 42%) as a pale brown solid.

1H NMR (300 MHz, CDC1₃) δ 7.64 (d, 1H), 7.56 (t, 1H), 7.00 (dd, 1H), 5.03 (dd, 2H), 4.18 (dd, 2H), 2.58 (s, 3H).

Intermediate 15: Preparation of l-acetyl-6-(6-methyl-pyridin-2-yl -2,3-dihydro- lH-imidazo[l,2-alimidazole-2-carboxylic acid ethyl ester

The procedure described for Intermediate 11 was repeated except that N- [5-(6-methyl-pyridin-2-yl)-lH-imidazol-2-yl]-acetamide (see Intermediate 11, 500 mg, 2.31 mmol) and 2,3-dibromo-propionic acid ethyl ester (1 mL, 6.93 mmol) were used instead of 1,2-dibromoethane, and MPLC on ΝΗ silica gel elution was conducted with CH₂Cl₂/EtOAC/hexane (3/0.5/1) to obtain the title compound (577.4 mg, 79%) as a brown oil.

1H NMR (300 MHz, CDC1₃) δ 7.69 (d, IH), 7.57 (t, IH), 7.42 (s, IH), 6.97 (d, IH), 5.36 (dd, IH), 4.40 (t, 2H), 4.25 (q, 2H), 4.14 (dd, 2H), 2.73 (s, 3H), 2.53 (s, 3H), 1.28 (t, 3H).

Intermediate 16: Preparation of l-acetyl-5-bromo-6-(6-methyl-pyridin-2-yl)-2,3- dihydro-lH-imidazo L2-a]imidazole-2-carboxylic acid ethyl ester

The procedure described for Intermediate 12 was repeated except that 1- acetyl-6-(6-methyl-pyridin-2-yl)-2,3-dihydro-lH-imidazo[l,2-a]imidazole-2- carboxylic acid ethyl ester (Intermediate 15, 577.4 mg, 1.83 mmol) was used instead of l-[6-(6-methyl-pyridin-2-yl)-2,3-dihydro-imidazo[l,2-a]imidazol-l- yl]-ethanone (Intermediate 11). The crude compound was purified by recrystallization from CH₂Cl₂/MeOH/hexane to obtain the title compound (414.7 mg, 57%) as a white solid.

^!H NMR (300 MHz, CDC1₃) δ 7.68 (d, IH), 7.59 (t, IH), 7.03 (d, IH), 5.37 (dd, IH), 4.35 (t, 2H), 4.27 (q, 2H), 4.12 (dd, 2H), 2.71 (s, 3H), 2.59 (s, 3H), 1.30 (t, 3H). Intermediate 17; Preparation of l-acetyl-6-(6-methyl-pyridin-2-yl)-2,3-dihydro- lH-imidazo[T,2-a imidazole-2-carbonitrile

The procedure described for Intermediate 11 was repeated except that N- [5-(6-methyl-pyridin-2-yl)-lH-imidazol-2-yl]-acetamide {see the procedure described for Intermediate 11, 500 mg, 2.31 mmol) and 2,3-dibromo-propionic acid ethyl ester (762 μΐ,, 6.93 mmol) were used instead of 1,2-dibromoethane, and MPLC on ΝΗ silica gel elution was conducted with CH₂Cl₂/EtOAC/hexane (3/0.5/1) to obtain the title compound (345.8 mg, 56%) as a pale brown foam.

Ή NMR (300 MHz, CDC1₃) S 7.67 (d, 1H), 7.59 (t, 1H), 7.49 (s, 1H), 7.01 (d, 1H), 5.61 (dd, 1H), 4.47 (m, 2H), 2.74 (s, 3H), 2.54 (s, 3H). Intermediate 18: Preparation of l-acetyl-5-bromo-6-(6-methyl-pyridin-2-yl)-2,3-

The procedure described for Intermediate 12 was repeated except that 1- acetyl-6-(6-methyl-pyridin-2-yl)-2,3-dihydro-lH-imidazo[l,2-a]imidazole-2- carbonitrile (Intermediate 17, 577.4 mg, 1.83 mmol) was used instead of l-[6-(6- methyl-pyridin-2-yl)-2,3-dihydro-imidazo[ 1 ,2-a]imidazol- 1 -yl]-ethanone

(Intermediate 11). The crude compound was purified by recrystallization from CH₂Cl₂/MeOH/hexane to obtain the title compound (240 mg, 53%) as a white solid.

H NMR (300 MHz, CDC1₃) δ 7.63 (d, 1H), 7.59 (t, 1H), 7.04 (dd, 1H), 5.61 (dd, 1H), 4.40 (m, 2H), 2.70 (s, 3H), 2.56 (s, 3H).

Example 1; Preparation of l-[6-(6-methyl-pyridin-2-yI)-5-quirioxalin-6-yl- 2,3-dihydro-imidazo[l,2-a]imidazoI-l-yl]-ethanone

1,2-Dibromoethane (56 μΐ_^, 0.65 mmol) was added to a mixture of N-[5- (6-methyl-pyridin-2-yl)-4-quinoxalin-6-yl-lH-imidazol-2-yl]-acetamide (150 mg, 0.44 mmol) and K₂CO₃ (304 mg, 2.20 mmol) in CH₃CN (6 mL) at 80 °C. 1,2- dibromoethane (25 μL, 0.29 mmol) was added thereto in three portions every 2 hours, and the reaction mixture was stirred for 15 hours. After cooling to room temperature, the mixture was filtered through celite, washed with CH₂C1₂, and concentrated under a reduced pressure. The residue was purified by MPLC on NH silica gel eluting with CH₂C1₂ to obtain the title compound (36.7 mg, 23%) as a yellow solid.

MS (ESI) m/z 371.68 (MH⁺).

1H NMR (300 MHz, CDC1₃) δ 8.84 (d, 2H), 8.15 (d, 1H), 8.03 (d, 1H), 7.97 (dd, 1H), 7.62 (d, 1H), 7.55 (t, 1H), 7.00 (d, 1H), 4.55 (t, 2H), 4.27 (t, 2H), 2.76 (s, 3H), 2.36 (s, 3H).

Example 2: Preparation of 6-[2-(6-methyl-pyridin-2-yI)-6,7-dihydro-5H- imidazo[l,2-a]imidazol-3-yl]-quinoxaline

IN NaOH (97 0.097 mmol) was added to a suspension of l-[6-(6- methyl-pyridin-2-yl)-5-quinoxalin-6-yl-2,3-dihydro-imidazo[l,2-a]imidazol-l- yl]-ethanone (Example 1, 30 mg, 0.08 mmol) in MeOH (2 mL), and the mixture was stirred at 60 °C for 2 hours. After cooling to room temperature, the reaction mixture was concentrated under a reduced pressure. The residue was purified by MPLC on NH silica gel eluting with 1% MeOH/CH₂Cl₂ to obtain the title compound (18.7 mg, 71%) as a yellow solid.

MS (ESI) m/z 329.64 (MH⁺).

l NMR (300 MHz, CDC1₃) δ 8.82 (d, 1H), 8.80 (d, 1H), 8.12 (t, 1H), 7.98 (m, 2H), 7.50 (d, lH), 7.49 (t, 1H), 6.97 (dd, 1H), 4.57 (br s, 1H), 4.24 (m, 2H), 4.09 (t, 2H), 2.39 (s, 3H).

Example 3: Preparation of 6-[2-(6-methyl-pyridin-2-yl)-5,6,7,8-tetrahydro- imidazo[l,2-a]pyrimidin-3-yl]-quinoxaline

A solution of bromine (0.117 mL, 2.28 mmol) in 1,4-dioxane (2 mL) were slowly added to a stirred solution of l-(6-methyl-pyridin-2-yl)-2-quinoxalin-6-yl- ethanone (600 mg, 2.28 mmol) in 1,4-dioxane (10 mL). After stirring for 1 hour, the reaction mixture was partitioned between f-BuOMe and water. The organic layer was separated and the aqueous layer was neutralized with a NaHCO₃ solution. The organic layer was mixed with the aqueous layer and separated. The aqueous layer was extracted twice with CH₂C1₂, dried over anhydrous Na₂SO₄, filtered and evaporated to dryness under a reduced pressure to obtain the bromide (877 mg, 1 12%). Tetrahydro-pyrimidin-2-ylideneamine hydrochloride (330 mg, 2.44 mmol) and K₂CO₃ (337 mg, 2.44 mmol) were added to a solution of the bromide (278 mg, 0.81 mmol) in DMF (3 mL), and the mixture was stirred at 80 °C for 5 hours. After cooling to room temperature, the reaction mixture was diluted with THF (5 mL), filtered through celite, and washed with THF. The filtrate was concentrated under a reduced pressure. The residue was purified by MPLC on NH silica gel eluting with 1% MeOH/CH₂Cl₂ and recrystallized with EtOAc/hexane to obtain the title compound (42 mg, 15%) as an orange solid.

MS (ESI) m/z 343.69 (MH⁺).

1H NMR (300 MHz, CDC1₃) δ 8.84 (d, 1H), 8.83 (d, 1H), 8.09 (d, 1H), 8.02 (d, 1H), 7.84 (dd, 1H), 7.40 (t, 1H), 7.27 (d, 1H), 6.90 (d, 1H), 4.97 (br s, 1H), 3.90 (t, 2H), 3.49 (m, 2H), 2.38 (s, 3H), 2.09 (quintet, 2H).

Example 4: Preparation of 6-[2-(6-methyl-pyridin-2-y_)-6,7-dihyd imidazo[l,2-a]imidazol-3-yl]-quinoline

1,2-Dibromoethane (56 μΐ., 0.65 mmol) was added to a mixture of N-[5- (6-methyl-pyridin-2-yl)-4-quinolin-6-yl-lH-imidazol-2-yl]-acetamide (150 mg, 0.44 mmol) and K₂CO₃ (304 mg, 2.20 mmol) in CH₃CN (6 mL) at 80 °C. After 2.5 hours, 1,2-dibromoethane (28 μΐ,, 0.33 mmol) was added thereto and the reaction mixture stirred for 20 hours. After cooling to room temperature, the mixture was filtered through celite, washed with CH₂C1₂, and concentrated under a reduced pressure. The residue was purified by MPLC on NH silica gel with eluting solvent (CH₂C1₂→ 10% EtOAc/CH₂Cl₂→ 2% MeOH/CH₂Cl₂) to obtain the cyclic compound (19.1 mg, 12%) as a pale yellow solid. IN NaOH (62 μL, 0.062 mmol) was added to a suspension of the cyclic compound (19.1 mg, 0.052 mmol) in MeOH (2 mL), and the mixture was stirred at 60 °C for 2-hours. After cooling to room temperature, the reaction mixture was concentrated under a reduced pressure. The residue was purified by MPLC on NH silica gel eluting with 1.5% MeOH/CH₂Cl₂ to obtain the title compound (10.9 mg, 64%) as a yellow solid. MS (ESI) m/z 329.64 (MH ).

1H NMR (300 MHz, CDC1₃) S 8.89 (dd, IH), 8.11 (m, IH), 8.03 (d, IH), 7.94 (d, IH), 7.82 (dd, IH), 7.45 (t, IH), 7.41 (d, IH), 7.39 (t, IH), 6.92 (dd, IH), 4.44 (br t, IH), 4.16 (m, 2H), 4.07 (m, 2H), 2.40 (s, 3H).

Example 5: Preparation of 6-[2-(6-methyI-pyridin-2-yI)-5,6,7,8-tetrahydro- imidazo[l,2-a]pyrimidin-3-yl]-quinoline

1,3-Dibromopropane (45 μΐ,, 0.44 mmol) was added to a mixture of N-[5-

(6-methyl-pyridin-2-y l)-4-quinolin-6-y 1- 1 H-imidazol-2-y l]-acetamide (100 mg, 0.29 mmol) and K₂CO₃ (200 mg, 1.45 mmol) in CH₃CN (4 mL) at 80 °C. After 2.5 hours, 1,3-dibromopropane (23 \L, 0.22 mmol) was added thereto and the reaction mixture was stirred for 2.5 hours. After cooling to room temperature, the mixture was filtered through celite, washed with CH2CI₂, and concentrated under a reduced pressure. The residue was purified by MPLC on NH silica gel eluting with MeOH/CH₂Cl₂ (0→ 2%) to obtain the cyclic compound (60.4 mg, 54%) as a pale yellow solid. IN NaOH (190 iL, 0.19 mmol) was added to a solution of the cyclic compound (60.4 mg, 0.16 mmol) in MeOH (3 mL), and the mixture was stirred at 60 °C for 1 hour. After cooling, the reaction mixture was concentrated under a reduced pressure. The residue was purified by MPLC on NH silica gel eluting with 1.5% MeOH /CH₂C1₂ and recrystallized from EtOAc to obtain the title compound (10.1 mg, 18%) as a yellow solid.

MS (ESI) m/z 342.86 (MH⁺).

1H NMR (300 MHz, CDC1₃) δ 8.92 (dd, IH), 8.13 (d, IH), 8.08 (d, IH),

7.86 (d, IH), 7.73 (dd, IH), 7.42 (dd, IH), 7.33 (t, IH), 7.14 (d, IH), 6.87 (d, IH), 4.90 (br s, III), 3.81 (t, 2H), 3.48 (m, 211), 2.40 (s, 3H), 2.09 (quintet 2H). Example 6; Preparation of 2-[2-(6-methyl-pyridin-2-yI)-6,7-dihydro-5H- imidazo[l,2-a]imidazoI-3-yI]-thieno 3,2-c]pyridine

l-[5-Bromo-6-(6-methyl-pyridin-2-yl)-2,3-dihydro-imidazo[l,2- a]imidazol-l-yl]-ethanone (Intermediate 12, 100 mg, 0.31 mmol), Pd(PPh₃)₄ (17.9 mg, 0.016 mmol) and CuBr (4.5 mg, 0.031 mmol) were added to a solution of 2-tributylstannanyl-thieno[3,2-c]pyridine (Intermediate 1, 158 mg, 0.37 mmol) in 1,4-dioxane (4.5 mL), and the mixture was stirred at 100 °C under N₂ for 14 hours. After cooling to room temperature, the mixture was filtered through celite, washed with CH₂C1₂, and concentrated under a reduced pressure. The residue was purified by MPLC on NH silica gel eluting with CH₂Cl₂/hexane/EtOAC (3/l/0.5→ 3/0/l→ 3/0/2) to obtain the coupled compound (83.5 mg, 72%) as a yellow solid. IN NaOH (259 pL, 0.259 mmol) was added to a suspension of the coupled compound (80.9 mg, 0.125 mmol) in MeOH (6.5 mL), and the mixture was stirred at 70 °C for 1.5 hours. After cooling to room temperature, the reaction mixture was concentrated under a reduced pressure. The residue was purified by MPLC on NH silica gel eluting with MeOH/CH₂Cl₂ (1%→ 2%) to obtain the title compound (61.6 mg, 86%) as a yellow solid.

MS (ESI) m/z 334.77 (MH⁺).

1H NMR (300 MHz, CDCl₃+CD₃OD) δ 8.89 (s, 1H), 8.27 (d, 1H), 7.67 (d, 1H), 7.63 (s, 1H), 7.55 (t, 1H), 7.43 (d, 1H), 7.02 (d, 1H), 4.26 (m, 2H), 4.04 (m, 2H), 2.52 (s, 3H).

Example 7: Preparation of 6-[2-(6-methyI-pyridin-2-yI)-6,7-dihydro-5H- imidazo [1 ,2-a] imidazol-3-yl] -benzothiazole

Pd(PPh₃)₄ (17.9 mg, 0.016 mmol) was added to a mixture of 6-(4,4,5,5- tetramethyl-[l,3,2]dioxaborolan-2-yl)-benzothiazole (Intermediate 2, 97.0 mg, 0.37 ' mmol), l-[5-bromo-6-(6-methyl-pyridin-2-yl)-2,3-dihydro-imidazo[l,2- a]imidazol-l-yl]-ethanone (Intermediate 12, 100 mg, 0.31 mmol), K₂CO₃ (85.7 mg, 0.62 mmol) in toluene (4.5 mL) and EtOH (0.23 mL), and the mixture was stirred at 100 °C under N₂ for 13 hours. After cooling to room temperature, the mixture was filtered through celite, washed with CH₂C1₂, and concentrated under a reduced pressure. The residue was purified by MPLC on NH silica gel eluting with CH₂Cl₂/hexane/EtOAC (3/1/0.5 → 3/1/1) and recrysallization from CH₂Cl₂/hexane to obtain the coupled compound (49.2 mg, 42%) as a white solid. To a suspension of the above compound (49.2 mg, 0.049 mmol) in MeOH (4.5 mL) was added IN NaOH (170 uL, 0.17 mmol) and the mixture was stirred at 70 °C for 1.3 hours. After cooling to room temperature, the reaction mixture was concentrated under a reduced pressure. The residue was diluted with water, neutralized with IN HC1, extracted twice with CH₂C1₂, dried over anhydrous MgSO₄, filtered and evaporated under a reduced pressure. The residue was purified by MPLC on NH silica gel eluting with MeOH/CH₂Cl₂ (1%→ 2%) to obtain the title compound (42.8 mg, 98%) as a pale yellow solid.

MS (ESI) m/z 334.70 (MH⁺).

1H NMR (300 MHz, CDC1₃) δ 9.00 (s, 1H), 8.17 (d, 1H), 8.10 (d, 1H), 7.60 (dd, 1H), 7.42 (t, 1H), 7.34 (d, 1H), 6.92 (d, 1H), 4.10 (m, 4H), 2.40 (s, 3H). Example 8: Preparation of 5-benzo[b]thiophen-5-yl-6-(6-methyl-pyridin-2- yI)-2,3-dihydro-lH-imidazo[l,2-a]imidazole

Pd(PPh₃)₄ (15 mg, 0.013 mmol) was added to a suspension of 2- benzo[b]thiophen-5-yl-4,4,5,5-tetramethyl-[l,3,2]dioxaborolane (Intermediate 3, 80.2 mg, 0.31 mmol), l-[5-bromo-6-(6-methyl-pyridin-2-yl)-2,3-dihydro- imidazo[l,2-a]imidazol-l-yl]-ethanone (Intermediate 12, 83 mg, 0.26 mmol), 2CO₃ (72 mg, 0.52 mmol) in toluene (4.5 mL) and EtOH (0.2 mL), and the mixture was stirred at 100 °C under N₂ for 16 hours. After cooling to room temperature, the mixture was filtered through celite, washed with CH₂C1₂, and concentrated under a reduced pressure. The residue was purified by MPLC on NH silica gel eluting with CH₂Cl₂/hexane/EtOAC (3/l/0.5→ 2/1/1) and recrysallization from CH₂Cl₂/hexane to obtain the coupled compound (18.2 mg, 19%) as a white solid. To a suspension of the above compound (18.2 mg, 0.049 mmol) in MeOH (2 mL) was added IN NaOH (63 μL, 0.063 mmol) and the mixture was stirred at 70 °C for 2 hours. After cooling to room temperature, the reaction mixture was concentrated under a reduced pressure. The residue was diluted with water, neutralized with IN HC1, extracted twice with CH₂C1₂, dried over anhydrous MgSO₄, filtered and evaporated under a reduced pressure. The residue was purified by MPLC on NH silica gel eluting with MeOH/CH₂Cl₂ (1% → 2%) to obtain the title compound (16.0 mg, 99%) as a pale brown solid.

MS (ESI) m/z 333.71 (MH⁺).

1H NMR (300 MHz, CDC1₃) δ 7.95 (d, 1H), 7.84 (d, 1H), 7.46 (d, 1H), 7.43 (dd, 1H), 7.38 (d, 1H), 7.32 (t, 1H), 7.26 (d, 1H), 6.90 (d, 1H), 4.35 (br s, 1H), 4.06 (m, 4H), 2.46 (s, 3H).

Example 9: Preparation of 6-[2-(6-methyI-pyridin-2-yl)-6,7-dihydro-5H- imidazo[l,2-a]imidazol-3-yl]-[l,2,4]triazolo[l,5-a]pyridine

The procedure described for Example 8 was repeated except that 6- (4,4,5, 5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-[l,2,4]triazolo[l,5-a]pyridine (Intermediate 4, 100 mg, 0.41 mmol) was used instead of 2-benzo[b]thiophen-5- yl-4,4,5,5-tetramethyl-[l,3,2]dioxaborolane, and MPLC on NH silica gel elution was conducted with CH₂Cl₂/EtOAC/hexane (3/1/0.5 → 3/0/1) to obtain the coupled compound (45.3 mg, 31%) as a white solid. The resulting compound was then reacted as described in Example 8 to afford after MPLC on NH silica gel eluting with MeOH/CH₂Cl₂ (1→ 2%), the title compound (35.7 mg, 89%) as a pale yellow solid.

MS (ESI) m/z 318.71 (MH⁺).

1H NMR (300 MHz, CDC1₃) δ 9.01 (t, 1H), 8.31 (s, 1H), 7.66 (m, 1H), 7.56 (d, 1H), 7.52 (t, 1H), 6.94 (dd, 1H), 5.39 (br s, 1H), 4.03 (m, 4H), 2.37 (s, 3H).

Example 10; Preparation of 5-[2-(6-methyl-pyridin-2-yl)-6,7-dihydro-5H- imidazo [ 1,2-a] imidazol-3-yl] -ben

The procedure described for Example 8 was repeated except that 5- (4,4,5, 5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-benzoxazole (Intermediate 5, 92.4 mg, 0.38 mmol) was used instead of 2-benzo[b]thiophen-5-yl-4,4,5,5- tetramethyl-[l,3,2]dioxaborolane, and MPLC on NH silica gel elution was conducted with CH₂Cl₂/EtOAC/hexane (3/1/1) and recrystallization from

CH₂Cl₂/hexane, to obtain the coupled compound (27.9 mg, 25%) as a white solid. The resulting compound was then reacted as described in Example 8 to afford after MPLC. on NH silica gel eluting with MeOH/CH₂Cl₂ (1→ 2%), the title compound (7.4 mg, 30%) as a pale yellow solid.

MS (ESI) m/z 318.69 (MH⁺).

1H NMR (300 MHz, CDC1₃) δ 8.12 (s, IH), 7.90 (s, IH), 7.55 (d, 2H),

7.41 (t, IH), 7.30 (d, IH), 6.90 (d, IH), 4.07 (m, 4H), 2.42 (s, 3H).

Example 11: Preparation of 4-[2-(6-methyl-pyridin-2-yl)-6,7-dihydro-5H- imidazo[l,2-a]imidazol-3-yl]-quinoline

The procedure described for Example 8 was repeated except that 4- (4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-quinoline (Intermediate 6, 92.3 mg, 0.36 mmol) was used instead of 2-benzo[b]thiophen-5-yl-4,4,5,5- tetramethyl-[l,3,2]dioxaborolane, and MPLC on NH silica gel elution was conducted with CH₂Cl₂/EtOAC/hexane (2/0.5/1 -→ 2/1/0) to obtain the coupled compound (18.4 mg, 17%) as a pale yellow solid. The resulting compound was then reacted as described in Example 8 to afford after MPLC on NH silica gel eluting with MeOH/CH₂Cl₂ (1%→ 2%), the title compound (14.8 mg, 91%) as a yellow solid.

MS (ESI) m/z 328.74 (MH⁺).

1H NMR (300 MHz, CDC1₃) δ 8.94 (d, IH), 8.14 (d, IH), 7.82 (d, IH), 7.69 (m, IH), 7.45 (d, IH), 7.39 (m, IH), 7.33 (t, IH), 7.22 (d, IH), 6.79 (d, IH), 4.57 (br s, IH), 4.06 (t, 2H), 3.90 (m, 2H), 2.09 (s, 3H).

Example 12: Preparation of 5-benzo[l,3]dioxol-5-yl-6-(6-methyl-pyridin-2- yl)-2,3-dihydro-lH-imidazo[l,2-a]imidazole

The procedure described for Example 8 was repeated except that 5- (4,4,5, 5-tetramethyl-[ 1 ,3,2]dioxaborolan-2-yl)-benzo[ 1 ,3]dioxole (Intermediate 7, 92 mg, 0.37 mmol) was used instead of 2-benzo[b]thiophen-5-yl-4,4,5,5- tetramethyl-[l,3,2]dioxaborolane and MPLC on NH silica gel elution was conducted with CH₂Cl₂/EtOAC/hexane (2/0.5/1) and recrystallization from CH₂Cl₂/hexane, to obtain the coupled compound (34.0 mg, 30%) as a white solid. The resulting compound was then reacted as described in Example 8 to afford after MPLC on NH silica gel eluting with MeOH/CH₂Cl₂ (1 → 2%), the title compound (26.5 mg, 88%) as a pale brown solid.

MS (ESI) m/z 321.61 (MH⁺).

1H NMR (300 MHz, CDC1₃) δ 7.40 (t, 1H), 7.26 (d, 1H), 6.98 (d, 1H), 6.91 (m, 2H), 6.80 (d, 1H), 5.98 (s, 2H), 4.35 (br s, 1H), 4.02 (m, 4H), 2.48 (s, 3H).

Example 13: Preparation of 5-(2,3-dihydro-benzo[l,4]dioxin-6-yI)-6-(6- methyl-pyridin-2-yl)-2,3-dihydro-lH-imidazo[l,2-a]imidazole

The procedure described for Example 8 was repeated except that 6-

(4,4,5, 5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-2,3-dihydro-benzo[l,4]dioxine (Intermediate 8, 98 mg, 0.37 mmol) was used instead of 2-benzo[b]thiophen-5- yl-4,4,5,5-tetramethyl-[l,3,2]dioxaborolane, and MPLC on NH silica gel elution was conducted with CH₂Cl₂/EtOAC/hexane (3/0.5/1) and recrystallization from CH₂Cl₂/hexane to obtain the coupled compound (33.3 mg, 29%) as a white solid. The resulting compound was then reacted as described in Example 8 to afford after MPLC on NH silica gel eluting with MeOH/CH₂Cl₂ (1→ 2%), the title compound (28.5 mg, 96%) as a pale brown solid.

MS (ESI) m/z 335.69 (MH⁺).

1H NMR (300 MHz, CDC1₃) δ 7.39 (t, 1H), 7.17 (d, 1H), 6.90 (d, 1H),

6.88 (d, 1H), 6.83 (dd, 1H), 6.77 (d, 1H), 4.23 (m, 4H), 3.97 (m, 4H), 2.42 (s, 3H).

Example 14: Preparation of 7-[2-(6-methyl-pyridin-2-yl)-6,7-dihydro-5H- imidazo[l,2-a]imidazol-3-yl]-2-pyrazol-l-yl-quinoxaline

The procedure described for Example 8 was repeated except that 2- pyrazol-l-yl-7-(4,4,5,5-tetramethyl-[l,3,2]dioxaborolan-2-yl)-quinoxaline

(Intermediate 10, 102 mg, O.35mmol) was used instead of 2-benzo[b]thiophen-5- yl-4,4,5,5-tetramethyl-[l,3,2]dioxaborolane, and MPLC on NH silica gel elution was conducted with CH₂Cl₂/EtOAC/hexane(2/0.5/l) and recrystallization from CH₂Cl₂/hexane to obtain the coupled compound (52.6 mg, 39%) as a white solid. The resulting compound was then reacted as described in Example 8 to afford after MPLC on NH silica gel eluting with MeOH/CH₂Cl₂ (1→2%) and recrystallization three times from CH₂Cl₂/hexane, the title compound (25.4 mg, 53%) as an orange solid.

MS (ESI) m/z 395.78 (MH⁺).

1H NMR (300 MHz, CDCl₃+CD₃OD) S 9.56 (s, 1H), 8.67 (d, 1H), 8.02 (d, 1H), 7.96 (d, 1H), 7.84 (m, 1H), 7.77 (dd, 1H), 7.51 (t, 1H), 7.41 (d, 1H), 6.97 (d, 1H), 6.56 (m, 1H), 4.23 (m, 2H), 4.06 (m, 2H), 2.36 (s, 3H).

Example 15: Preparation of dimethyI-(2-{7-[2-(6-methyl-pyridin-2-yl)-6,7- dihydro-5H-imidazo[l,2-a]imidazol-3-yI]-quinoxalin-2-yloxy}-ethyl)-amine

2-Dimethylaminoethanol (0.6 mL) was added to a suspension of l-[6-(6- methyl-pyridin-2-yl)-5-(3-pyrazol-l-yl-quinoxalin-6-yl)-2,3-dihydro- imidazo[l,2-a]imidazol-l-yl]-ethanone (see the procedure described for Example 14, 25.5 mg, 0.058 mmol) and K₂CO₃ (24.2 mg, 0.175 mmol) in DMF (0.8 mL), and the mixture was stirred at 120 °C for 4 hours. After cooling to room temperature, the mixture was concentrated under a reduced pressure. The residue was diluted with water, neutralized with IN HCl, extracted three times with CH₂C1₂, dried over anhydrous MgSO₄, filtered and evaporated under a reduced pressure. The residue was purified by MPLC on NH silica gel eluting with MeOH/CH₂Cl₂ (1 → 2%) to obtain the title compound (10.5 mg, 43%) as a yellow solid.

MS (ESI) m/z 416.57 (MH⁺).

1H NMR (300 MHz, CDC1₃) δ 8.48 (s, 1H), 7.91 (s, 1H), 7.89 (d, 1H), 7.68 (dd, 1H), 7.46 (t, 1H), 7.40 (d, 1H), 6.95 (d, 1H), 4.89 (br s, 1H), 4.58 (t, 2H), 4.22 (m, 2H), 4.09 (m, 2H), 2.79 (t, 2H), 2.42 (s, 3H), 2.37 (s, 6H).

Example 16; Preparation of 2-methoxy-7-[2-(6-methyl-pyridin-2-yl)-6,7- dihydro-5H-imidazo[l,2-a]imidazol-3-yl]-quinoxaline

IN NaOH (37 μί,, 0.037 mmol) was added to a suspension of l-[5-(3- imidazol-l-yl-quinoxalin-6-yl)-6-(6-methyl-pyridin-2-yl)-2,3-dihydro- imidazo[l,2-a]imidazol-l-yl]-ethanone (prepared from Intermediate 9 as described in Example 8, 12.3 mg, 0.028 mmol) in MeOH (2 mL), and the mixture was stirred at 70 °C for 1 hour. After cooling to room temperature, the mixture was concentrated under a reduced pressure. The residue was diluted with water, neutralized with IN HCl, extracted three times with CH₂C1₂, dried over anhydrous MgSO₄, filtered and evaporated under a reduced pressure. The residue was purified by MPLC on NH silica gel eluting with MeOH/CH₂Cl₂ (1→ 2%) to obtain the title compound (9.4 mg, 94%) as a yellow solid.

MS (ESI) m/z 359.74.

1H NMR (400 MHz, CDC1₃) δ 8.42 (s, 1H), 7.93 (d, 1H), 7.90 (d, 1H), 7.68 (dd, 1H), 7.46 (t, 1H), 7.40 (d, 1H), 6.95 (d, 1H), 4.46 (br s, 1H), 4.22 (m, 2H), 4.09 (s, 3H), 4.07(m, 2H), 2.43 (s, 3H).

Example 17: Preparation of 5-(3,5-dimethoxyphenyl)-6-(6-methyIpyridin-2- yI)-2,3-dihydro-lH-imidazo[l,2-a]imidazole

The procedure described for Example 8 was repeated except that 2-(3,5- dimethoxyphenyl)-4,4,5,5-tetramethyl-l,3,2-dioxaborolane (79 mg, 0.3 mmol) was used instead of 2-benzo[b]thiophen-5-yl-4,4,5,5-tetramethyl- [l,3,2]dioxaborolane and MPLC on NH silica gel elution was conducted with CH₂Cl₂/EtOAC/hexane (2/0.5/4) to obtain the coupled compound (30 mg, 40%) as a white solid. The resulting compound was then reacted as described in Example 8 to afford after MPLC on NH silica gel eluting with MeOH/CH₂Cl₂ (1 → 3%), the title compound (6.9 mg, 26%) as an off-white solid.

MS (ESI) m/z 337.27 (MH+)

1H NMR (300 MHz, CDC1₃) δ 7.41 (t, 1H), 7.29 (d, 1H), 6.92 (d, 1H),

6.61 (d, 2H), 6.41 (t, 1H), 4.09 (dd, 2H), 4.00 (dd, 2H), 3.74 (s, 6H), 2.51 (s, 3H).

Example 18: Preparation of A,A^LdimethyI-4-(6-(6-methylpyridin-2-yI)-2,3- dihydro-lH-imidazo[l,2-a]imidazoI-5-yl)aniline

The procedure described for Example 8 was repeated except that (4- (dimethylamino)phenyl)boronic acid (50 mg, 0.3 mmol) was used instead of 2- benzo[b]thiophen-5-yl-4,4,5,5-tetramethyl-[l,3,2]dioxaborolane, and MPLC on NH silica gel elution was conducted with CH₂Cl₂/EtOAC/hexane (2/0.5/4) to obtain the coupled compound (20 mg, 28%) as a white solid. The resulting compound was then reacted as described in Example 8 to afford after MPLC on NH silica gel eluting with MeOH/CH₂Cl₂ (1→ 3%), the title compound (10.4 mg, 58%) as an off- white solid.

MS (ESI) m/z 320.34 (MH+)

1H NMR (300 MHz, CDC1₃) δ 7.33 (m, 3H), 7.21 (m, 1H), 6.88 (m, 1H), 6.71 (m, 2H), 4.00 (ddt, 4H), 2.98 (s, 6H), 2.49 (s, 3H).

Example 19: Preparation of 4-(6-(6-methyIpyridin-2-yl)-2,3-dihydro-lH- imidazo[l,2-a]imidazoI-5-yl)ben

The procedure described for Example 8 was repeated except that 4-

(4,4,5, 5-tetramethyl-l,3,2-dioxaborolan-2-yl)benzonitrile (103 mg, 0.45 mmol) was used instead of 2-benzo[b]thiophen-5-yl-4,4,5,5-tetramethyl- [l,3,2]dioxaborolane and MPLC on NH silica gel elution was conducted with CH₂Cl₂/Et0AC/hexane (2/0.5/4) to obtain the coupled compound (21 mg, 20%) as a yellow solid. The resulting compound was then reacted as described in Example 8 to afford after MPLC on NH silica gel eluting with MeOH/CH₂Cl₂ (1 → 3%), the title compound (11.1 mg, 61%) as a pale yellow solid.

MS (ESI) m/z 302.31 (MH+)

1H NMR (300 MHz, eDCl₃) S 7.57 (m, 5H), 7.39 (d, 1H), 7.01 (d, 1H), 4.09 (m, 4H), 2.40 (s, 3H).

Example 20: Preparation of 2-methyl-6-(6-(6-methylpyridin-2-yl)-2,3- dihydro-lH-imidazo[l,2-a]imidazol-5-yl)quinoline

The procedure described for Example 8 was repeated except that 2- methyl-6-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)quinoline (121 mg, 0.45 mmol) was used instead of 2-benzo[b]thiophen-5-yl-4,4,5,5-tetramethyl- [l,3,2]dioxaborolane and MPLC on NH silica gel elution was conducted with CH₂Cl₂/EtOAC/hexane (2/0.5/4) to obtain the coupled compound (47 mg, 41%) as a yellow solid. The resulting compound was then reacted as described in Example 8 to afford after MPLC on NH silica gel eluting with MeOH/CH₂Cl₂ (1 → 3%), the title compound (20.4 mg, 49%) as a yellow solid.

MS (ESI) m/z 342.35 (MH+)

1H NMR (300 MHz, CDC1₃) δ 7.94 (m, 3H), 7.77 (dd, 1H), 7.43 (m, 2H),

7.28 (d, 1H), 6.93 (d, 1H), 4.10 (m, 4H), 2.75 (s, 3H), 2.38 (s, 3H).

Example 21; Preparation of 4-(6-(6-methylpyridin-2-yI)-2,3-dihyd imidazo [1 ,2-a] i midazol-5-y l)aniline

The procedure described for Example 8 was repeated except that 4- (4,4,5, 5-tetramethyl-l,3,2-dioxaborolan-2-yl)aniline (66 mg, 0.3 mmol) was used instead of 2-benzo[b]thiophen-5-yl-4,4,5,5-tetramethyl-[l,3,2]dioxaborolane and MPLC on NH silica gel elution was conducted with C]¾Cl₂/EtOAC/hexane (2/0.5/4) to obtain the coupled compound (33 mg, 49%) as a brown solid. The resulting compound was then reacted as described in Example 8 to afford after MPLC on NH silica gel eluting with MeOH CH₂Cl₂ (1 → 3%), the title compound (18.0 mg, 63%) as a pale brown solid.

MS (ESI) m/z 292.30 (MH+)

1H NMR (300 MHz, CDC1₃) S 7.41 (t, 1H), 7.19 (m, 3H), 6.91 (d, 1H),

6.68 (m, 2H), 4.00 (m, 4H), 3.29 (br s, 2H, NH₂), 2.46 (s, 3H).

Example 22: Preparation of A^-(4-(6-(6-methylpyridin-2-yl)-2,3-dihydro-lH- imidazo[l,2-a]imidazol-5-yl)phen l)acetamide

The procedure described for Example 8 was repeated except that N-(4- (4,4,5, 5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl)acetamide (79 mg, 0.3 mmol) was used instead of 2-benzo[b]thiophen-5-yl-4,4,5,5-tetramethyl- [l,3,2]dioxaborolane and MPLC on ΝΗ silica gel elution was conducted with CH₂Cl₂/EtOAC/hexane (2/0.5/4) to obtain the coupled compound (23 mg, 31%) as a yellow solid. The resulting compound was then reacted as described in Example 8 to afford after MPLC on ΝΗ silica gel eluting with MeOH/CH₂Cl₂ (1 → 3%), the title compound (2.2 mg, 11%) as a pale yellow solid.

MS (ESI) m/z 334.30 (MH+)

1H NMR (300 MHz, CDC1₃) δ 7.44 (m, 5H), 7.27 (d, 1H), 6.92 (d, 1H), 4.02 (m, 4H), 2.44 (s, 311), 2.17 (s, 311). Example 23: Preparation of A'-(4-(6-(6-methylpyridin-2-yI)-2,3-dihydro-lH- imidazo[l,2-a]imidazol-5-yl)ph amide

The procedure described for Example 8 was repeated except that 4-

(4,4,5, 5-tetramethy ,3,2-dioxaborolan-2-yl)aniline (132 mg, 0.6 mmol) was used instead of 2-benzo[b]thiophen-5-yl-4,4,5,5-tetramethyl-

[l,3,2]dioxaborolane and MPLC on NH silica gel elution was conducted with CH₂Cl₂/EtOAC/hexane (2/0.5/4) to obtain the coupled compound (66 mg, 49%) as a brown solid.

Methanesulfonyl chloride (33 μΐ,, 0.4 mmol) was added to a solution of the coupled compound (66mg, 0.2 mmol) and triethylamine (111 μΐ,, 0.8 mmol) in dry CH₂C1₂ (2 mL), and the mixture was stirred at 40 °C under N₂ for 1 hour. After cooling to room temperature, the mixture was diluted with brine and CH₂C1₂, and stirred for 5 minutes. After separating organic layer, the aqueous layer was extracted three times with CH₂C1₂, dried over Na₂SO₄, filtered, and concentrated under a reduced pressure. The residue was purified by MPLC on NH silica gel eluting solvent (CH₂Cl₂/hexane EtOAC (3/1/1)→ MeOH/CH₂Cl₂ (1/20)). The resulting compound was then reacted with IN NaOH as described in Example 8 to afford after MPLC on NH silica gel eluting with MeOH/CH₂Cl₂ (3 → 10%), the title compound (34.7 mg, 47% in two steps) as a pale brown solid.

MS (ESI) m/z 370.07 (MH+)

1H NMR (300 MHz, CDC1₃) δ 7.42 (t, 1H), 7.30 (m, 2H), 7.21 (d, 1H), 7.14 (m, 2H), 6.89 (d, 1H), 3.98 (m, 4H), 2.94 (s, 3H), 2.34 (s, 3H).

Example 24: Preparation of tert-butyl (4-(6-(6-methylpyridin-2-yI)-2,3- dihydro-lH-imidazo[l,2-a]imidazol-5-yI)phenyi)carbamate

The procedure described for Example 8 was repeated except that teri-butyl (4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl) carbamate (144 mg, 0.45 mmol) was used instead of 2-benzo[b]thiophen-5-yl-4,4,5,5-tetramethyl- [l,3,2]dioxaborolane and MPLC on NH silica gel elution was conducted with CH₂Cl₂ EtOAC/hexane (2/0.5/4) to obtain the coupled compound (33 mg, 25%) as a white solid. The resulting compound was then reacted as described in Example 8 to afford after MPLC on NH silica gel eluting with MeOH/CH₂Cl₂ (1 → 3%), the title compound (12.4 mg, 42%) as an off- white solid.

MS (ESI) m/z 392.16 (MH+)

1H NMR (300 MHz, CDC1₃) δ 7.42 (t, 2H), 7.35 (m, 4H), 7.24 (d, 1H), 6.92 (d, 1H), 4.01 (m, 4H), 2.45 (s, 3H), 1.53 (s, 9H). Example 25: Preparation of 5-(4-(4-methylpiperazin-l-yl)phenyI)-6-(6- methylpyridin-2-yl)-2,3-dih dro-lH-imidazo[l,2-a]imidazole

The procedure described for Example 8 was repeated except that 1- methyl-4-(4-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl)piperazine (136 mg, 0.45 mmol) was used instead of 2-benzo[b]thiophen-5-yl-4,4,5,5- tetramethyl-[l,3,2]dioxaborolane and MPLC on NH silica gel elution was conducted with CH₂Cl₂/EtOAC/hexane (2/0.5/4) to obtain the coupled compound

(58 mg, 46%) as a white solid. The resulting compound was then reacted as described in Example 8 to afford after MPLC on NH silica gel eluting with MeOH/CH₂Cl₂ (1→ 3%), the title compound (53.9 mg, 99%) as an off- white solid.

MS (ESI) m/z 375.37 (MH+)

1H NMR (300 MHz, CDC1₃) δ 7.40 (t, 1H), 7.32 (m, 2H), 7.22 (d, 1H),

6.90 (m, 3H), 3.99 (m, 4H), 3.25 (dd, 4H), 2.60 (dd, 4H), 2.47 (s, 3H), 2.36 (s, 3H).

Example 26: Preparation of 4-(4-(6-(6-methylpyridin-2-yl)-2,3-dihydro-lH- imidazo[l,2-a]imidazol-5-yI henyl)morphoIine

The procedure described for Example 8 was repeated except that 4-(4- (4,4,5, 5-tetramethyl-l,3,2-dioxaborolan-2-yl)phenyl)morpholine (131 mg, 0.45 mmol) was used instead of 2-benzo[b]thiophen-5-yl-4,4,5,5-tetramethyl- [l,3,2]dioxaborolane and MPLC on NH silica gel elution was conducted with CH₂Cl₂/EtOAC/hexane (2/0.5/4) to obtain the coupled compound (66 mg, 55%) as a white solid. The resulting compound was then reacted as described in Example 8 to afford after MPLC on NH silica gel eluting with MeOH/CH₂Cl₂ (1 → 3%), the title compound (34.5 mg, 58%) as an off- white solid.

MS (ESI) m/z 362.42 (MH+)

1H NMR (300 MHz, CDC1₃) δ 7.41 (t, 1H), 7.33 (m, 2H), 7.22 (d, 1H), 6.89 (m, 3H), 4.01 (m, 4H), 3.88 (dd, 4H), 3.20 (dd, 4H), 2.47 (s, 3H). Example 27: Preparation of 6-(6-methyIpyridin-2-yl)-5-(m-tolyl)-2,3- dihydro-lH-imidazo [1,2-a] imidazole

The procedure described for Example 8 was repeated except that m- tolylboronic acid (62 mg, 0.45 mmol) was used instead of 2-benzo[b]thiophen-5- yl-4,4,5,5-tetramethyl-[l,3,2]dioxaborolane and MPLC on NH silica gel elution was conducted with CH₂Cl₂/EtOAC/hexane (2/0.5/4) to obtain the coupled compound (34 mg, 34%) as a white solid. The resulting compound was then reacted as described in Example 8 to afford after MPLC on NH silica gel eluting with MeOH/CH₂Cl₂ (1→ 3%), the title compound (31.3 mg, 99%) as an off- white solid.

MS (ESI) m/z 291.32 (MH+)

1H NMR (300 MHz, CDC1₃) δ 7.41 (t, 1H), 7.26 (m, 4H), 7.10 (m, 1H), 6.91 (d, 1H), 4.03 (m, 4H), 2.46 (s, 3H), 2.34 (t, 3H). Example 28: Preparation of 5-(4-methoxyphenyl)-6-(6-methylpyridin-2-yl)- 2,3-dihydro-lH-imidazo[l,2-a]imidazoIe

The procedure described for Example 8 was repeated except that (4- methoxyphenyl)boronic acid (69 mg, 0.45 mmol) was used instead of 2- benzo[b]thiophen-5-yl-4,4,5,5-tetramethyl-[l,3,2]dioxaborolane and MPLC on NH silica gel elution was conducted with CH₂Cl₂/EtOAC/hexane (2/0.5/4) to obtain the coupled compound (42 mg, 40%) as a white solid. The resulting compound was then reacted as described in Example 8 to afford after MPLC on NH silica gel eluting with MeOH/CH₂Cl₂ (1→ 3%), the title compound (22.1 mg, 60%) as an off-white solid.

MS (ESI) m/z 307.30 (MH+)

1H NMR (300 MHz, CDC1₃) δ 7.39 (m, 3H), 7.26 (m, 1H), 6.90 (m, 3H), 4.02 (m, 4H), 3.84 (s, 3H), 2.46 (s, 3H).

Example 29: Preparation of 6-(6-methyIpyridin-2-yl)-5-(4-(trifluoromethyl) phenyl)-2,3-dihydro-lH-imidazo[l,2-a]imidazole

The procedure described for Example 8 was repeated except that (4- (trifluoromethyl)phenyl)boronic acid (86 mg, 0.45 mmol) was used instead of 2- benzo[b]thiophen-5-yl-4,4,5,5-tetramethyl-[l,3,2]dioxaborolane and MPLC on NH silica gel elution was conducted with CH₂Cl₂/EtOAC/hexane (2/0.5/4) to obtain the coupled compound (48 mg, 41%) as a white solid. The resulting compound was then reacted as described in Example 8 to afford after MPLC on NH silica gel eluting with MeOH/CH₂Cl₂ (1→ 3%), the title compound (22.0 mg, 52%) as an off- white solid.

MS (ESI) m/z 345.37 (MH+)

1H NMR (300 MHz, CDC1₃) δ 7.59 (m, 4H), 7.49 (t, 1H), 7.38 (d, 1H),

6.96 (d, 1H), 4.06 (m, 4H), 2.42 (s, 3H).

Example 30: Preparation of 6-(6-methylpyridin-2-yl)-5-(4-(methyIthio) phenyI)-2,3-dihydro-lH-imidazo[l,2-a]imidazole

The procedure described for Example 8 was repeated except that (4- (methylthio)phenyl)boronic acid (76 mg, 0.45 mmol) was used instead of 2- benzo[b]thiophen-5-yl-4,4,5,5-tetramethyl-[l,3,2]dioxaborolane and MPLC on NH silica gel elution was conducted with CH₂Cl₂/EtOAC/hexane (2/0.5/4) to obtain the coupled compound (19 mg, 17%) as a white solid. The resulting compound was then reacted as described in Example 8 to afford after MPLC on NH silica gel eluting with MeOH/CH₂Cl₂ (1→ 3%), the title compound (6.1 mg, 37%) as an off- white solid.

MS (ESI) m/z 323.29 (MH+)

1H NMR (300 MHz, CDC1₃) δ 7.41 (m, 3H), 7.27 (m, 3H), 6.92 (d, 1H), 4.03 (m, 4H), 2.51 (s, 3H), 2.46 (s, 3H). Example 31: Preparation of 5-(3-fluoro-4-methoxyphenyl)-6-(6- methyIpyridin-2-yI)-2,3-dihyd -lH-imidazo[l,2-a]imidazole

The procedure described for Example 8 was repeated except that (3- fluoro-4-methoxyphenyl)boronic acid (77 mg, 0.45 mmol) was used instead of 2- benzo[b]thiophen-5-yl-4,4,5,5-tetramethyl-[l,3,2]dioxaborolane and MPLC on NH silica gel elution was conducted with CH₂Cl₂/EtOAC/hexane (2/0.5/4) to obtain the coupled compound (26 mg, 24%) as a white solid. The resulting compound was then reacted as described in Example 8 to afford after MPLC on NH silica gel eluting with MeOH/CH₂Cl₂ (1→ 3%), the title compound (21.0 mg, 90%) as an off-white solid.

MS (ESI) m/z 325.36 (MH+)

1H NMR (300 MHz, CDC1₃) δ 7.45 (t, 1H), 7.31 (m, 2H), 7.17 (ddd, 1H), 6.93 (m, 2H), 4.03 (m, 4H), 3.92 (s, 3H), 2.45 (s, 3H).

Example 32: Preparation of 5-(4-fluorophenyI)-6-(6-methylpyridin-2-yl)-2,3- dihydro-lH-imidazo[l,2-a]imidazole

The procedure described for Example 8 was repeated except that (4- fluorophenyl)boronic acid (64 mg, 0.6 mmol) was used instead of 2- benzo[b]thiophen-5-yl-4,4,5,5-tetramethyl-[l,3,2]dioxaborolane and MPLC on NH silica gel elution was conducted with CH₂Cl₂/EtOAC/hexane (2/0.5/4) to obtain the coupled compound (40 mg, 40%) as a white solid. The resulting compound was then reacted as described in Example 8 to afford after MPLC on NH silica gel eluting with MeOH CH₂Cl₂ (1→ 3%), the title compound (25.6 mg, 72%) as an off- white solid.

MS (ESI) m/z 295.38 (MH+)

1H NMR (300 MHz, CDC1₃) δ 7.45 (m, 3H), 7.31 (d, 1H), 7.04 (m, 2H), 6.90 (d, 1H), 4.03 (m, 4H), 2.43 (s, 3H).

Example 33: Preparation of l-acetyI-6-(6-methyl-pyridin-2-yl)-5-thieno[3,2- c]pyridin-2-yI-2,3-dihydro-lH-imidazo[l,2-a]imidazole-2-carboxylic acid ethyl ester

The procedure described for Example 6 was repeated except that 1-acetyl- 5-bromo-6-(6-methyl-pyridin-2-yl)-2,3-dihydro-lH-imidazo[l,2-a]imidazole-2- carboxylic acid ethyl ester (Intermediate 16, 414.7 mg, 1.05 mmol) was used instead of l-[5-bromo-6-(6-methyl-pyridin-2-yl)-2,3-dihydro-imidazo[l,2- a]imidazol-l-yl]-ethanone and MPLC on NH silica gel elution was conducted with CH₂Cl₂/hexane/EtOAC (3/1/0→ 3/1/1), to obtain the title compound (298.4 mg, 64%) as an off-white solid.

MS (ESI) m/z 448.31 (MH+)

1H NMR (300 MHz, CDC1₃) S 9.05 (s, 1H), 8.43 (d, 1H), 7.80 (s, 1H), 7.72 (d, 1H), 7.67 (d, 1H), 7.61 (t, 1H), 7.07 (d, 1H), 5.44 (dd, 1H), 4.59 (t, 1H), 4.33 (dd, 1H), 4.29 (q, 2H), 2.76 (s, 3H), 2.56 (s, 3H), 1.32 (t, 3H). Example 34; Preparation of 6-(6-methyl-pyridin-2-yl)-5-thieno[3,2- c]pyridin-2-yl-2,3-dihydro-lH-imidazo[l,2-a]imidazole-2-carboxylic acid ethyl ester

K₂CO₃ (152 mg, 1.1 mmol) was added to a solution of l-acetyl-6-(6- methyl-pyridin-2-yl)-5-thieno[3,2-c]pyridin-2-yl-2,3-dihydro-lH-imidazo[l,2- a]imidazole-2-carboxylic acid ethyl ester (Example 33, 50 mg, 0.11 mmol) in EtOH/ CH₂C1₂ (1/1, 2 mL), and the mixture was stirred for 2 hours and then at 50

°C for 2.5 hours. After cooling to room temperature, the mixture was filtered through celite, washed with 5% MeOH/CH₂Cl₂ and concentrated under a reduced pressure. The residue was purified by MPLC on NH silica gel eluting with CH₂C1₂ to obtain the title compound (4.5 mg, 10%) as a pale brown solid.

MS (ESI) m/z 406.19 (MH+)

1H NMR (300 MHz, CDC1₃) δ 9.02 (d, 1H), 8.40 (d, 1H), 7.74 (s, 1H),

7.70 (d, 2H), 7.58 (s, 1H), 7.56 (d, 1H), 7.03 (t, 1H), 4.94 (br s, 1H), 4.83 (dd, 1H), 4.57 (t, 1H), 4.54 (d, 1H), 4.30 (q, 2H), 2.58 (s, 3H), 1.34 (t, 3H).

Example 35: Preparation of [6-(6-methyI-pyridin-2-yI)-5-thieno[3,2- c]pyridin-2-yl-2,3-dihydro- -imidazo[l,2-a]imidazol-2-yl]-methanol

NaBH₄ (32 mg, 0.88 mmol) was added to a solution of l-acetyl-6-(6- methyl-pyridin-2-yl)-5-thieno[3,2-c]pyridin-2-yl-2,3-dihydro-lH-imidazo[l,2- a]imidazole-2-carboxylic acid ethyl ester (Example 33, 50 mg, 0.11 mmol) in EtOH (2 niL) and CH₂C1₂ (0.5ml) at 0 °C, and the mixture was stirred for 1 hour. The reaction mixture was quenched with H₂O (1 mL) and then added sat. aqueous NH C1 solution. The mixture was extracted three times with CH₂C1₂. The organic layers were combined, dried over Na₂SO₄, filtered, and concentrated under a reduced pressure. The residue was purified by recrystallization from CH₂Cl₂/MeOH/Hexane to afford the title compound (31.7 mg, 79%) as a yellow solid.

MS (ESI) m/z 364.32 (MH+)

1H NMR (300 MHz, CDC1₃) δ 8.83 (s, 1H), 8.22 (d, 1H), 7.64 (d, 1H), 7.55 (s, 1H), 7.53 (t, 1H), 7.36 (d, 1H), 7.00 (d, 1H), 4.40 (m, 1H), 4.30 (t, 1H), 4.03 (dd, 1H), 4.68 (dd, 1H), 3.61 (dd, 1H), 2.50 (s, 3H).

Example 36: Preparation of l-acetyl-6-(6-methyl-pyridin-2-yl)-5-thieno[3,2- c] pyridin-2-yl-2,3-dihydro-lH-imid zo [1 ,2-a] imidazole-2-carbonitrile

The procedure described for Example 6 was repeated except that 1-acetyl- 5-bromo-6-(6-methyl-pyridin-2-yl)-2,3-dihydro- lH-imidazo[ 1 ,2-a]imidazole-2- carboxylic acid ethyl ester (Intermediate 18, 240 mg, 0.69 mmol) was used instead of 1 -[5-bromo-6-(6-methyl-pyridin-2-yl)-2,3-dihydro-imidazo[ 1 ,2- a]imidazol-l-yl]-ethanone. The crude product was purified by MPLC on NH silica gel eluting with CH₂Cl₂/hexane/EtOAC (3/1/1) and then recrystallization from CH₂Cl₂/MeOH/Hexane to afford the title compound (168.3 mg, 61%) as a pale brown solid.

MS (ESI) m/z 401.19 (MH+)

1H NMR (300 MHz, CDC1₃) δ 8.97 (s, 1H), 8.34 (d, 1H), 7.73 (d, 1H), 7.72 (s, 1H), 7.59 (m, 2H), 7.07 (m, 1H), 5.69 (dd, 1H), 4.61 (m, 2H), 2.71 (s, 3H), 2.50 (s, 3H).

Example 37: Preparation of 6-(6-methyl-pyridin-2-yl)-5-thieno[3,2- c]pyridin-2-yI-2,3-dihydro-l -imidazo[l,2-a]imidazole-2-carbonitrile

IN NaOH (80 xL, 0.08 mmol) was added to a solution of l-acetyl-6-(6- methyl-pyridin-2-yl)-5-thieno[3,2-c]pyridin-2-yl-2,3-dihydro- lH-imidazo[ 1 ,2- a]imidazole-2-carbonitrile (Example 36, 50 mg, 0.13 mmol) in MeOH (1 niL) and l,4-dioxane (4 ml), and the mixture was stirred for 1 hour. The reaction mixture was quenched with sat. aqueous NH C1 solution and then added H₂0. The mixture was extracted three times with CH₂C1₂. The organic layers were combined, dried over Na₂SO₄, filtered, and concentrated under a reduced pressure. The residue was purified by MPLC on NH silica gel eluting with MeOH/CH₂Cl₂ (0% → 2%) to afford the title compound (5.4 mg, 12%) as an off-white solid.

MS (ESI) m/z 359.23 (MH+)

1H NMR (300 MHz, CDC1₃) δ 8.86 (s, 1H), 8.24 (d, 1H), 7.66 (d, 1H), 7.56 (s, 1H), 7.51 (d, 1H), 7.36 (d, 1H), 7.02 (d, 1H), 5.10 (dd, 1H), 4.49 (m, 2H), 2.47 (s, 3H).

Example 38: Preparation of 6-(6-methyl-pyridin-2-yl)-5-thieno[3,2- c]pyridin-2-yI-2,3-dihydro-lH-imidazo[l,2-a]imidazole-2-carboxyIic acid amide

H₂SO₄ (0.5 mL) was added to a mixture of l-acetyl-6-(6-methyl-pyridin- 2-yl)-5-thieno[3,2-c]pyridin-2-yl-2,3-dihydro-lH-imidazo[l,2-a]imidazole-2- carbonitrile (Example 36_> 50 mg, 0.13 mmol) in MeOH (0.5 mL), and the mixture was stirred for 30 minutes. The reaction mixture was neutralized with sat. aqueous NaHCO₃ solution and IN NaOH. The mixture was extracted three times with MeOH/CH₂Cl₂. The organic layers were combined, dried over Na₂SO₄, filtered, and concentrated under a reduced pressure. The residue was purified by recrystallization from the mixture of CH₂Cl₂ MeOH/Hexane to afford the title compound (28.4 mg, 60%) as an off-white solid.

MS (ESI) m/z 359.27 (M-H₂O)

1H NMR (300 MHz, CDC1₃) δ 8.85 (d, 1H), 8.24 (d, 1H), 7.66 (d, 1H), 7.56 (s, lH), 7.51 (d, 1H), 7.36 (d, lH), 7.02 (d, 1H), 5.10 (dd, lH), 4.49 (m, 2H), 2.47 (s, 3H). Example 39: Preparation of (6-(6-methylpyridin-2-yI)-5-(thieno[3,2- c]pyridin-2-yl)-2,3-dihydro-lH-imidazo[l,2-a]imidazol-2-yI)methanamine

LiAlH₄ solution (1.0 M in tetrahydrofuran, 1.5 mL) was added to a solution of l-acetyl-6-(6-methyl-pyridin-2-yl)-5-thieno[3,2-c]pyridin-2-yl-2,3- dihydro-lH-imidazo[l,2-a]imidazole-2-carbonitrile (Example 36, 200 mg, 0.5 mmol) in dry tetrahydrofuran (5 mL) at 0 °C under N₂, and the mixture was stirred for 3 hours. After cooling down to -10 °C, the solution was quenched with H₂O (57 μΐ.), IN NaOH (114 μΓ), and H₂O (171 μΐ ) sequentially. The resulting slurry was filtered. The mixture was diluted with H₂O and EtOAC, and stirred for 5 minutes. After separating organic layer, the aqueous layer was extracted three times with CH₂C1₂. The organic layer was dried over Na₂SO₄, filtered, and concentrated under a reduced pressure. The residue was purified by MPLC on ΝΉ silica gel eluting with MeOH/CH₂Cl₂ (5%) to afford the title compound (115 mg, 63%) as a bright yellow solid.

MS (ESI) m/z 363.28 (MH+)

1H NMR (300 MHz, CDC1₃) δ 9.00 (d, 1H), 8.39 (m, 1H), 7.70 (m, 2H), 7.56 (m, 2H), 7.03 (m, 1H), 4.40 (m, 2H), 4.09 (m, 1H), 3.04 (dd, 1H), 2.92 (dd, 1H), 2.59 (s, 3H).

Example 40: Preparation of A-((6-(6-methylpyridin-2-yI)-5-(thieno[3,2- c] pyridin-2-yl)-2,3-dihydro-lH-imidazo [1,2-a] imidazol-2- yl)methyl)acetamide

Acetic anhydride (20.8 μΐ,, 0.22 mmol) was added to a solution of (6-(6- methylpyridin-2-yl)-5-(thieno[3,2-c]pyridin-2-yl)-2,3-dihydro-lH-imidazo[l,2- a]imidazol-2-yl)methanamine (Example 39, 36 mg, 0.1 mmol) and N,N- diisopropylethylamine (19.1 μL, 0.11 mmol) in dry CH₂C1₂ (1 mL) under N₂, and the mixture was stirred for 1 hour. The mixture was diluted with H₂O and CH₂C1₂, and stirred for 5 minutes. After separating organic layer, the aqueous layer was extracted two times with CH₂C1₂. The organic layer was dried over Na₂SO₄, filtered, and concentrated under a reduced pressure. The residue was purified by MPLC on NH silica gel eluting with MeOH/CH₂Cl₂ (5%) to obtain the title compound (12 mg, 30%) as a yellow solid.

MS (ESI) m/z 405.24 (MH+)

1H NMR (300 MHz, CDC1₃) δ 8.95 (s, 1H), 8.34 (d, 1H), 7.72 (d, 1H), 7.60 (m, 2H), 7.44 (d, 1H), 7.08 (d, 1H), 4.54 (m, 1H), 4.37 (dd, 1H), 4.00 (dd, 1H), 3.52 (m, 2H), 2.58 (s, 3H), 1.99 (s, 3H).

Example 41: Preparation of 6-(6-methylpyridin-2-yl)-5-(thieno[3,2- c] py ridin-2-yl)-2,3-dihydroimi le

The procedure described for Example 6 was repeated except that 5-bromo- 6-(6-methylpyridin-2-yl)-2,3-dihydroimidazo[2,l-b]oxazole (Intermediate 14, 35 mg, 0.125 mmol) was used instead of l-[5-bromo-6-(6-methyl-pyridin-2-yl)-2,3- dihydro-imidazo[l,2-a]imidazol-l-yl]-ethanone and MPLC on NH silica gel elution was conducted with CH₂Cl₂/hexane/EtOAC (3/1/0.5→ 3/0/1→ 3/0/2), to obtain the title compound (8 mg, 19%) as a tan solid.

MS (ESI) m/z 335.17 (MH+)

1H NMR (300 MHz, CDC1₃) δ 9.03 (d, 1H), 8.42 (d, 1H), 7.86 (d, 1H),

7.72 (dt, 1H), 7.63 (m, 2H), 7.05 (ddd, 1H), 5.13 (dd, 2H), 4.44 (dd, 2H), 2.58 (s, 3H).

Biological Data

The biological activity of the compound of the present invention was assessed using the following assays:

Test Example 1: Cell-Free Assay for Evalutating Inhibition of ALK5 Kinase Phosphorylation

The kinase activity of ALK5 was assessed by measuring radiolabeled phosphate [ P] incorporation into the generic substrate, casein. The kinase domain of human AL 5 (200^th to 503^th amino acids) was fused to the N-terminal GST/histidine tag and the kinase construct was engineered to be expressed from insect cells. The purified ALK5 protein was mixed with the casein substrate (final concentration, 2 mg/mL), and reaction buffer (containing 20 mM Hepes (pH 7.5), 10 mM MgCl₂, 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na₃VO₄, 2 mM DTT and 1% DMSO) was added thereto. DMSO solution of each test compound of formula (I) having different concentrations was prepared using pure DMSO, and each solution was delivered to the reaction mixture. ³³P- ATP (specific activity 0.01 μθϊ/μΐ final) was delivered into the reaction mixture thus obtained for initiating the reaction, followed by incubation at room temperature for 2 hours. After incubation, the reaction solution was spotted onto P81 ion exchange paper, the paper was washed extensively with 0.75% phosphoric acid. Then, the paper was air-dried and counted.

The inventive compounds typically exhibited IC₅₀ values of less than 10 μΜ; some exhibited IC₅₀ values of less than 1 μΜ; and some even exhibited IC₅₀ values less than 50 nM {see Table 1).

Test Example 2: Cell-Free Assay for Evaluating Inhibition of ALK4 Kinase Phosphorylation

The kinase activity of AL 4 was assessed by measuring radiolabeled phosphate [³³P] incorporation into the generic substrate, casein. The kinase domain of human ALK4 (150^th to 505^th amino acids) was fused to GST tag and the kinase construct was engineered to be expressed from insect cells.

Inhibition of the ALK4 kinase phosphorylation by test compounds of formula (I) was determined in a manner similar to that described in Test Example

1 except for using ALK4 instead of ALK5.

The inventive compounds typically exhibited IC₅₀ values of less than 10 μΜ; some exhibited IC₅o values of less than 1 μΜ; and some even exhibited IC50 values of less than 50 nM.

Test Example 3: Assay for Evaluating Cellular Inhibition of TGF-β Signaling

Biological activity of the inventive compound of formula (I) was determined by measuring their ability to inhibit TGF-pi-induced-Smad binding element-luciferase (SBE-Lux) reporter activity and PAI-l-luciferase (p3TP-Lux) reporter activity in HaCaT cells. HaCaT cells were cultured in DMEM medium (containing 10% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin) at 37 ^°C in a 5% CO₂ incubator. The cells were plated at a concentration of 2.5 ^χ 10⁴ cells/well in 96 well plates, and transfected with 0.6 μg of p3TP-Lux and SBE- Lux reporter construct, respectively. 24 hours after the trasnfection, the cells were pre-treated with varying concentration (5, 10, 50, 100 and 500 nM) of AL 5 inhibitor for 2 hours. The cells thus obtained were then stimulated with 5 ng/ml of TGF-βΙ ligand (PEPROTECH, 100-21C) and incubated at 37 ^°C in a 5% CO₂ incubator for 24 hours. The media was washed out, and the luciferase activity in cell lysates was determined by luciferase assay system (Promega).

The IC₅₀ value of the inventive compound of formula (I) was calculated from dose-response curves generated using Prism software.

The inventive compound of formula (I) typically exhibited IC₅₀ values of less than 10 μΜ; some exhibited IC₅₀ values of less than 1 μΜ; and some even exhibited IC₅₀ values of less than 50 nM.

While the invention has been described with respect to the above specific embodiments, it should be recognized that various modifications and changes may be made to the invention by those skilled in the art which also fall within the scope of the invention as defined by the appended claims.

Claims

WHAT IS CLAIMED IS:

1. A compound of formula (I), a pharmaceutically acceptable salt or solvate thereof:

wherein,

Rj is phenyl, pyridyl or thienyl fused with a structural moiety which, together with two ring members of said phenyl, pyridyl or thienyl, forms a 5-7 membered aromatic or non-aromatic ring, wherein said ring optionally contains up to three heteroatoms independently selected from O, N and S, and the fused phenyl, pyridyl or thienyl ring is optionally substituted with one or more groups independently selected from halo, -O-Ci_-6 alkyl, -S-Ci_-6 alkyl, -C_1-6 alkyl, -C_\.₆ haloalkyl, CN, -(CH₂)_p-OR4, -0-(CH₂)_q-NR₄R₅, -(CH₂)_P-NR4R₅, -NHCO-O- (CH₂)_q-NR₄R₅, -NHCO-(CH₂)_p-NR₄R₅, or -C₅._I5 heteroaryl containg up to three heteroatoms independently selected from O, N and S; or Ki is phenyl or pyridyl optionally substituted with one or more groups independently selected from halo, -O-Ci_-6 alkyl, -S-C_1-6 alkyl, -C_1-6 alkyl, -C_1-6 haloalkyl, -CN, -(CH₂)_p-OR₄₎ -O- (CH₂)_q-NR₄R₅, -NH-(CH₂)_q-NR₄R₅, -(CH₂)_P-NR₄R₅, -(CH^-NHCOR^ -(CH₂)_P- NHCO₂R_4; -(CH₂)_p-NHSO₂R₄ or -C₅.₁₅ heterocycle, said -C_5-15 heterocycle containg up to three heteroatoms independently selected from O, N and S and being optionally substituted with C],₆ alkyl;

R₂ is H, halo, -O-C_1-6 alkyl, -S-C_1-6 alkyl, -C_1-6 alkyl, -C_3-7 cycloalkyl, -C₅.₁₅ heteroaryl, -C_1-6 haloalkyl, -O-(CH₂)_p-NR₄R_5, -(CH₂)_p-NR₄R₅, CN, - CONHR,, or -SO₂ HR₄;

R₃ is H, -O-C_1-6 alkyl, -S-C_1-6 alkyl, -C_1-6 alkyl, -C₃.₇ cycloalkyl, -(CH₂)_P- NR_fRs, -O-(CH₂)_q-NR₄R₅, -(CH₂)_p-CONHOH, -(CH₂)_P-CN, -(CH₂)_p-CO₂R4, - (CH₂)_p-CONR₄R₅, -(CH₂)_p-tetrazole, -(CH₂)_p-COR₄, -(CH₂)_q-(OR₆)₂, -(CH₂)_p- OR₄, -(CH₂)_P-CH=CH-CN, -(CH₂)_p-CH=CH-CO₂R₄, -(CH₂)_p-CH=CH-CONR₄R₅, -(CH₂)_p-NHCOR₄, -(CH₂)_p-NHCO₂R_4> -(CH₂)_p-NHSO₂R₄, or -(CH₂)_p-CH=CH- tetrazole;

R4 and R₅ are independently H or -C_1-6 alkyl; or R₄ and R₅, together with the nitrogen atom to which they are attached, form a 3 to 6-membered aromatic or non-aromatic ring, wherein said ring optionally contains up to three heteroatoms independently selected from O, N, and S;

Re is -C_1-6 alkyl;

p is an integer ranging from 0 to 4;

q is an integer ranging from 2 to 5;

n is an integer ranging from 1 to 3;

X is NR₇, O, or S; and

R₇ is H, OH, -C_1-6 alkyl, -C_3-7 cycloalkyl, or -CO-Ci_-6 alkyl.

2. The compound of claim 1, wherein

Ri is phenyl, pyridyl or thienyl fused with a structural moiety which, together with two ring members of said phenyl, pyridyl or thienyl, forms a 5-6 membered aromatic or non-aromatic ring, wherein said ring optionally contains one or two heteroatoms independently selected from O, N and S, and the fused phenyl, pyridyl or thienyl ring is optionally substituted with one or more groups independently selected from halo, -O-C_1-6 alkyl, -S-C_1-6 alkyl, -C_1-6 alkyl, -Ci_-6 haloalkyl, -CN, -(CH₂)_p-OR_4, -O-(CH₂)_q-NR₄R₅, -(CH₂)_P-NR₄R₅, -NHCO-O- (CH₂)_q-NR₄R₅, -NHCO-(CH₂)_p-NR₄R₅, or -C₅.₁₅ heteroaryl containg up to three heteroatoms independently selected from O, N and S; or Ri is phenyl optionally substituted with one or more groups independently selected from halo, -O-C_1-6 alkyl, -S-C_1-6 alkyl, -C_1-6 alkyl, -C_1-6 haloalkyl, CN, -NH-(CH₂)_q-NR₄R₅, -(CH₂)_P- NR₄R₅, -(CH₂)_p-NHCOR₄, -(CH₂)_p-NHCO₂R_4, -(CH₂)_p-NHSO₂R₄, or -C_5-15 heterocycle, said -C_5-i₅ heterocycle containg up to three heteroatoms independently selected from O, N and S and being optionally substituted with Q. 6 alkyl;

R₂ is halo, -O-C_1-6 alkyl, -S-C_1-6 alkyl, -Cj_-6 alkyl, -C_3-7 cycloalkyl, -C5.15 heteroaryl, -C_1-6haloalkyl, -(CH₂)_p-OR_4j -O-(CH₂)p-NR₄R₅₎ -(CH₂)_P-NR₄R₅, -CN, - CONHR₄, or -SO₂NHR₄;

R₃ is H, -0-C_1-6 alkyl, -S-C_1-6 alkyl, -C_1-6 alkyl, C_3-7 cycloalkyl, -(CH₂)_P- NR₄R₅, -O-CCHz N _tRs, -(CH₂)_p-CONHOH, -(CH₂)_P-CN, -(CH₂)_p-CO₂R₄, - (CH₂)_p-CONR4R₅, -(CH₂)_p-tetrazole, -(CH₂)_p-OR₄, -(CH₂)_p-NHCOR₄, -(CH₂)_P- NHC0₂R4, or -(CH₂)_p-NHSO₂R4;

R₄ and R₅ are independently H or -CM alkyl; or R₄ and R₅ together with the nitrogen atom to which they are attached, form a 3 to 6-membered aromatic or non-aromatic heterocyclic ring containing up to three heteroatoms independently selected from O, N and S;

p is an integer ranging from 0 to 2;

q is an integer ranging from 2 to 4;

n is an integer of 1 or 2;

X is NR₇, O, or S; and

R₇ is H, OH, -Ci_-6 alkyl, or -CO-C_1-6 alkyl.

3. The compound of claim 1, wherein

R_! is a fused ring selected from the group consisting of quinoxalinyl, quinoiinyl, thienopyridinyl, benzothiazolyl, benzothiophenyl, triazolopyridinyl, benzoxazolyl, quinoiinyl, benzodioxolyl and benzodioxinyl, wherein said fused ring is optionally substituted with one or more groups independently selected from halo, -O-Ci_-6 alkyl, -S-C_1-6 alkyl, -C_1-6 alkyl, -C_1-6 haloalkyl, CN, -(CH₂)_P- OR,, -O-(CH₂)_q-NR₄R₅, -(CH₂)_p-NR₄R₅, or -C_5-i₅ heteroaryl, said heteroaryl containing one or two heteroatoms independently selected from O, N and S; or R] is phenyl optionally substituted with one or two groups independently selected from halo, -O-C_1-6 alkyl, -S-C_1-6 alkyl, -Ci_-6 alkyl, -C_1-6 haloalkyl, -CN, -(CH₂)_P- OR₄₎ -O-(CH₂)_q-NR₄R₅, -NH-(CH₂)_q-NR₄R₅, -(CH₂)_P-NR₄R₅, -(eH₂)_p-NHCOR₄, - (CH₂)_p-NHCO₂R_4; -(CH₂)_p-NHSO₂R₄ or -C_5-i₅ heterocycle, said heterocycle containing one or two heteroatoms independently selected from O, N and S and being optionally substituted with C_1-6 alkyl;

R₂ is halo, -C_1-6 alkyl, -C_1-6 haloalkyl, or -NH₂, and is positioned ortho to the nitrogen of the pyridyl ring;

R₃ is H, -O-C_1-6 alkyl, -S-C_1-6 alkyl, -C_1-6 alkyl, -(<¾)_Ρ-Μ^₅, -(CH₂)_P- CN, -(CH₂)_p-CO₂R4, -(CH₂)_p-CONR₄R₅, -(CH₂)_p-COR₄, -(CH₂)_p-OR₄, or -(CH₂)_p- NHCOR4;

R₄ and R₅ are independently H or -Ci_-6 alkyl;

p is an integer ranging from 0 to 2;

q is an integer ranging from 2 to 4;

n is an integer ranging from 1 to 3;

X is NR₇, O, or S; and

R₇ is H, or -CO-C^alkyl.

4. The compound of claim 1, which is selected from the group consisting of:

1) 1 -[6-(6-Methyl-pyridin-2-yl)-5-quinoxalin-6-y 1-2,3 -dihydro- imidazof 1 ,2-a]imidazol- 1 -yl]-ethanone;

2) 6-[2-(6-Methyl-pyridin-2-yl)-6,7-dihydro-5H-imidazo[l,2-a]imidazol- 3-yl]-quinoxaline;

3) 6-[2-(6-Methyl-pyridin-2-yl)-5,6,7,8-tetrahydro-imidazo[l,2- a]py rimidin- 3 -y 1] -quinoxaline ;

4) 6-[2-(6-Methyl-pyridin-2-yl)-6,7-dihydro-5H-imidazo[ 1 ,2-a]imidazol- 3-yl]-quinoline;

6) 2-[2-(6-Methyl-pyridin-2-yl)-6,7-dihydro-5H-imidazo[ 1 ,2-a]imidazol- 3 -yl]-thieno[3 ,2-c]pyridine;

7) 6-[2-(6-Methyl-pyridin-2-yl)-6,7-dihydro-5H-imidazo[ 1 ,2-a]imidazol- 3 -y 1] -benzothiazole;

8) 5-Benzo[b]thiophen-5-yl-6-(6-methyl-pyridin-2-yl)-2,3-dihydro-lH- imidazo[l,2-a]imidazole;

10) 5-[2-(6-Methyl-pyridin-2-yl)-6,7-dihydro-5H-imidazo[l,2-a]imidazol- 3-yl]-benzoxazole;

12) 5-Benzo[l,3]dioxol-5-yl-6-(6-methyl-pyridin-2-yl)-2,3-dihydro-lH- imidazo [ 1 ,2-a] imidazole;

13) 5-(2,3-Dihydro-benzo[l,4]dioxin-6-yl)-6-(6-methyl-pyridin-2-yl)-2,3- dihydro-lH-imidazo[l,2-a]imidazole;

17) ^" 5-(3,5-Dimethoxyphenyl)-6-(6-methylpyridin-2-yl)-2,3-dihydro- 1H- imidazo[ 1 ,2-a]imidazole;

18) N₎N-Dimethyl-4-(6-(6-methylpyridin-2-yl)-2,3-dihydro- 1H- imidazo[l,2-a]imidazol-5-yl)aniline;

20) 2-Methyl-6-(6-(6-methy lpyridin-2-y l)-2,3-dihy dro- 1 H-imidazo[ 1 ,2- a] imidazol- 5 -y l)quinoline ;

21) 4-(6-(6-Methylpyridin-2-yl)-2,3-dihydro- lH-imidazo[l,2-a]imidazol- 5-yl)aniline;

22) N-(4-(6-(6-Methylpyridin-2-yl)-2,3-dihydro-lH-imidazo[l,2- a] imidazol- 5-yl)phenyl)acetamide;

24) tert-Butyl (4-(6-(6-methylpyridin-2-yl)-2,3-dihydro-lH-imidazo[l,2- a] imidazol- 5 -yl)pheny l)carbamate;

25) 5-(4-(4-Methylpiperazin-l-yl)phenyl)-6-(6-methylpyridin-2-yl)-2,3- dihydro- lH-imidazo[ 1 ,2-a] imidazole;

26) 4-(4-(6-(6-fflMethylpyridin-2-yl)-2,3-dihydro-lH-imidazo[l,2- a]imidazol-5-yl)phenyl)morpholine;

27) 6-(6-Methylpyridin-2-yl)-5-(m-tolyl)-2,3-dihydro-lH-imidazo[l,2- a] imidazole;

28) 5-(4-Methoxyphenyl)-6-(6-methylpyridin-2-yl)-2,3-dihydro-lH- imidazo[ 1 ,2-a] imidazole;

30) 6-(6-Methylpyridin-2-yl)-5-(4-(methylthio) phenyl)-2,3-dihydro-lH- imidazo [ 1 ,2-a] imidazole;

31) 5-(3-Fluoro-4-methoxyphenyl)-6-(6-methylpyridin-2-yl)-2,3-dihydro- lH-imidazo[ 1 ,2-a]imidazole;

34) 6-(6-Methyl-pyridin-2-yl)-5-thieno[3,2-c]pyridin-2-yl-2,3-dihydro-lH- imidazo[l,2-a]imidazole-2-carboxylic acid ethyl ester;

35) [6-(6-Methyl-pyridin-2-yl)-5-thieno[3,2-c]pyridin-2-yl-2,3-dihydro- 1 H-imidazo[ 1 ,2-a] imidazol-2-y 1] -methanol ;

36) l-Acetyl-6-(6-methyl-pyridin-2-yl)-5-thieno[3,2-c]pyridin-2-yl-2,3- dihydro-lH-imidazo[l,2-a]imidazole-2-carbonitrile;

37) 6-(6-Methyl-pyridin-2-yl)-5-thieno[3,2-c]pyridin-2-yl-2,3-dihydro-lH- imidazo[l,2-a]imidazole-2-carbonitrile;

38) 6-(6-Methyl-pyridin-2-yl)-5-thieno[3,2-c]pyridin-2-yl-2,3-dihydro-lH- imidazo[l,2-a]imidazole-2-carboxylic acid amide;

40) N-((6-(6-Methylpyridin-2-yl)-5-(thieno[3,2-c]pyridin-2-yl)-2,3- dihydro- lH-imidazo[ 1 ,2-a]imidazol-2-yl)methyl)acetamide; and

41) 6-(6-Methylpyridin-2-yl)-5-(thieno[3,2-c]pyridin-2-yl)-2,3- dihydroimidazo[2,l-b]oxazole.

5 A use of the compound of claim 1 for the manufacture of a medicament for preventing or treating a disease mediated by transforming growth factor-β (TGF-β) type I receptor (ALK5) or activin type I receptor (ALK4), or both AL 5 and ALK4 receptors in a mammal.

6. The use of claim 5, wherein the disease mediated by ALK5 or ALK4 receptors, or both ALK5 and ALK4 receptors is selected from the group consisting of renal-, liver- or pulmonary fibrosis, glomerulonephritis, diabetic nephropathy, lupus nephritis, hypertension-induced nephropathy, renal interstitial fibrosis, renal fibrosis resulting from complications of drug exposure, HIV- associated nephropathy, transplant necropathy, liver fibrosis due to all etiologies, hepatic dysfunction attributable to infections, alcohol-induced hepatitis, disorders of the biliary tree, pulmonary fibrosis, acute lung injury, adult respiratory distress syndrome, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, pulmonary fibrosis due to infectious or toxic agents, post-infarction cardiac fibrosis, congestive heart failure, dilated cardiomyopathy, myocarditis, vascular stenosis, restenosis, atherosclerosis, ocular scarring, corneal scarring, proliferative vitreoretinopathy, excessive or hypertrophic scar or keloid formation in the dermis occurring during wound healing resulting from trauma or surgical wounds, peritoneal and sub-dermal adhesion, scleroderma, fibrosclerosis, progressive systemic sclerosis, dermatomyositis, polymyositis, arthritis, osteoporosis, ulcers, impaired neurological function, male erectile dysfunction, Alzheimer's disease, Raynaud's syndrome, fibrotic cancers, tumor metastasis growth, radiation-induced fibrosis and thrombosis.

7. The use of claim 5, wherein the mammal is a human.

8. A pharmaceutical composition for preventing or treating a disease mediated by ALK5 or ALK4 receptors, or both ALK5 and AL 4 receptors, which comprises the compound of formula (I) or its pharmaceutically acceptable salt or solvate of claim 1 as an active ingredient, and a pharmaceutically acceptable diluent or carrier.

9. The pharmaceutical composition of claim 8, wherein the disease mediated by ALK5 or AL 4 receptors, or both ALK5 and ALK4 receptors is selected from the group consisting of renal-, liver- or pulmonary fibrosis, glomerulonephritis, diabetic nephropathy, lupus nephritis, hypertension-induced nephropathy, renal interstitial fibrosis, renal fibrosis resulting from complications of drug exposure, HIV-associated nephropathy, transplant necropathy, liver fibrosis due to all etiologies, hepatic dysfunction attributable to infections, alcohol-induced hepatitis, disorders of the biliary tree, pulmonary fibrosis, acute lung injury, adult respiratory distress syndrome, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, pulmonary fibrosis due to infectious or toxic agents, postinfarction cardiac fibrosis, congestive heart failure, dilated cardiomyopathy, myocarditis, vascular stenosis, restenosis, atherosclerosis, ocular scarring, corneal scarring, proliferative vitreoretinopathy, excessive or hypertrophic scar or keloid formation in the dermis occurring during wound healing resulting from trauma or surgical wounds, peritoneal and sub-dermal adhesion, scleroderma, fibrosclerosis, progressive systemic sclerosis, dermatomyositis, polymyositis, arthritis, osteoporosis, ulcers, impaired neurological function, male erectile dysfunction, Alzheimer's disease, Raynaud's syndrome, fibrotic cancers, tumor metastasis growth, radiation- induced fibrosis and thrombosis.

10. A method for preventing or treating a disease mediated by AL 5 or ALK4 receptors, or both AL 5 and ALK4 receptors in a mammal, which comprises administering the compound of formula (I) or its pharmaceutically acceptable salt or solvate of claim 1 to the mammal in need thereof.

11. The method of claim 10, wherein the disease mediated by ALK5 or ALK4 receptors, or both ALK5 and ALK4 receptors is selected from the group consisting of renal-, liver- or pulmonary fibrosis, glomerulonephritis, diabetic nephropathy, lupus nephritis, hypertension-induced nephropathy, renal interstitial fibrosis, renal fibrosis resulting from complications of drug exposure, HIV- associated nephropathy, transplant necropathy, liver fibrosis due to all etiologies, hepatic dysfunction attributable to infections, alcohol-induced hepatitis, disorders of the biliary tree, pulmonary fibrosis, acute lung injury, adult respiratory distress syndrome, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, pulmonary fibrosis due to infectious or toxic agents, post-infarction cardiac fibrosis, congestive heart failure, dilated cardiomyopathy, myocarditis, vascular stenosis, restenosis, atherosclerosis, ocular scarring, corneal scarring, proliferative vitreoretinopathy, excessive or hypertrophic scar or keloid formation in the dermis occurring during wound healing resulting from trauma or surgical wounds, peritoneal and sub-dermal adhesion, scleroderma, fibrosclerosis, progressive systemic sclerosis, dermatomyositis, polymyositis, arthritis, osteoporosis, ulcers, impaired neurological function, male erectile dysfunction, Alzheimer's disease, Raynaud's syndrome, fibrotic cancers, tumor metastasis growth, radiation-induced fibrosis and thrombosis.

The method of claim 10, wherein the mammal is a human.